4-hydroxybenzyl group - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	4-hydroxybenzyl group	go back to main search page
Accession:	CHEBI:50336	browse the term
Synonyms:	exact_synonym:	4-hydroxybenzyl
	related_synonym:	Formula=C7H7O; SMILES=C1=C(C*)C=CC(=C1)O; tyrosine side-chain

show annotations for term's descendants Sort by:
Rat (468) Mouse (464) Human (483) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (464)

3,3',5'-triiodo-L-thyronine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

B cell leukemia/lymphoma 2

multiple interactions
increases activity

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of BCL2 protein]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

deiodinase, iodothyronine, type I

multiple interactions
increases metabolic processing

[Aurothioglucose results in decreased activity of DIO1 protein] which affects the metabolism of Triiodothyronine, Reverse; [DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine; [Genistein results in decreased activity of DIO1 protein] which affects the metabolism of Triiodothyronine, Reverse; [Propylthiouracil results in decreased activity of DIO1 protein] which affects the metabolism of Triiodothyronine, Reverse; [xanthohumol results in decreased activity of DIO1 protein] which affects the metabolism of Triiodothyronine, Reverse; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine]

PMID:21565810 PMID:25962824

NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366

G

deiodinase, iodothyronine, type II

multiple interactions
decreases activity

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]]

NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812

G

insulin I

multiple interactions

Melatonin inhibits the reaction [Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Vitamin E inhibits the reaction [Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]]

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

nuclear receptor coactivator 2

multiple interactions

Triiodothyronine, Reverse promotes the reaction [THRA protein binds to NCOA2 protein]; Triiodothyronine, Reverse promotes the reaction [THRB protein binds to NCOA2 protein]

NCBI chr 1:13,209,329...13,444,451
Ensembl chr 1:13,209,329...13,444,307

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]]; Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

increases phosphorylation
multiple interactions

Triiodothyronine, Reverse results in increased phosphorylation of NFKBIA protein
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased phosphorylation of NFKBIA protein]

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

natriuretic peptide type B

multiple interactions
increases expression

Melatonin inhibits the reaction [Triiodothyronine, Reverse results in increased expression of NPPB mRNA]; Vitamin E affects the reaction [Triiodothyronine, Reverse results in increased expression of NPPB mRNA]

NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662

G

prolyl 4-hydroxylase, beta polypeptide

multiple interactions
affects binding

2,4-dichlorophenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; 4-nonylphenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; 4-octylphenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; bisphenol A inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; Pentachlorophenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; tetrachlorodian inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]

NCBI chr11:120,451,124...120,464,079
Ensembl chr11:120,451,124...120,464,079

G

peroxisome proliferator activated receptor alpha

decreases expression

Triiodothyronine, Reverse results in decreased expression of PPARA mRNA

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]]; Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

solute carrier family 2 (facilitated glucose transporter), member 4

multiple interactions
decreases expression

Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SLC2A4 mRNA]; Vitamin E affects the reaction [Triiodothyronine, Reverse results in decreased expression of SLC2A4 mRNA]

NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014

G

superoxide dismutase 1, soluble

multiple interactions
decreases expression

Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein]; Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SOD1 mRNA]; Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein; Vitamin E inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein]; Vitamin E inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SOD1 mRNA]

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

superoxide dismutase 2, mitochondrial

multiple interactions

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased expression of and results in increased activity of SOD2 protein]; Triiodothyronine, Reverse results in increased expression of and results in increased activity of SOD2 protein

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

thyroid hormone receptor alpha

multiple interactions

Triiodothyronine, Reverse promotes the reaction [THRA protein binds to NCOA2 protein]

NCBI chr11:98,631,539...98,659,832
Ensembl chr11:98,631,464...98,659,832

G

thyroid hormone receptor beta

increases activity
multiple interactions
affects binding

Triiodothyronine, Reverse results in increased activity of THRB protein
Triiodothyronine, Reverse promotes the reaction [THRB protein binds to NCOA2 protein]
Triiodothyronine, Reverse binds to THRB protein

PMID:21543282 PMID:31566444

NCBI chr14:4,429,599...4,810,538
Ensembl chr14:4,431,611...4,809,435

G

tumor necrosis factor

multiple interactions
increases secretion

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased secretion of TNF protein]

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

3,3',5'-triiodothyronine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

increases expression

3,3',5-triiodothyronine increases expression of Tnf protein in serum

RGD

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

3,3',5-triiodo-L-thyronine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

decreases activity

Triiodothyronine results in decreased activity of AADAT protein

NCBI chr 8:60,958,877...60,998,711
Ensembl chr 8:60,958,966...60,998,711

G

ATP-binding cassette, sub-family A member 1

increases expression

Triiodothyronine results in increased expression of ABCA1 mRNA

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family B member 11

decreases activity
increases expression
multiple interactions

Triiodothyronine results in decreased activity of ABCB11 protein
Triiodothyronine results in increased expression of ABCB11 mRNA
[BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCB11 mRNA

PMID:28437613 PMID:34902352

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 4

decreases activity

Triiodothyronine results in decreased activity of ABCB4 protein

NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231

G

ATP-binding cassette, sub-family C member 5

increases expression

Triiodothyronine results in increased expression of ABCC5 mRNA

NCBI chr16:20,150,053...20,245,178
Ensembl chr16:20,150,053...20,245,144

G

ATP-binding cassette, sub-family F member 3

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ABCF3 mRNA

NCBI chr16:20,367,309...20,380,357
Ensembl chr16:20,367,327...20,380,129

G

ATP binding cassette subfamily G member 5

multiple interactions
increases expression

[BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG5 mRNA
Triiodothyronine results in increased expression of ABCG5 mRNA

NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439

G

ATP binding cassette subfamily G member 8

increases expression
multiple interactions

Triiodothyronine results in increased expression of ABCG8 mRNA
[BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG8 mRNA

NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761

G

acetyl-Coenzyme A carboxylase alpha

multiple interactions
increases expression
increases activity

Triiodothyronine inhibits the reaction [Streptozocin results in decreased activity of ACACA protein]; Triiodothyronine inhibits the reaction [Streptozocin results in decreased expression of ACACA mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]
Triiodothyronine results in increased expression of ACACA mRNA
Triiodothyronine results in increased activity of ACACA protein

PMID:1973097 PMID:33476690

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

acyl-Coenzyme A binding domain containing 4

decreases expression

Triiodothyronine results in decreased expression of ACBD4 mRNA

NCBI chr11:102,992,524...103,003,026
Ensembl chr11:102,992,508...103,005,229

G

angiotensin I converting enzyme

multiple interactions

Triiodothyronine results in increased expression of and results in increased activity of ACE protein

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

acyl-CoA thioesterase 1

increases expression
decreases expression

Triiodothyronine results in increased expression of ACOT1 mRNA
Triiodothyronine results in decreased expression of ACOT1 mRNA

PMID:15953391 PMID:28299817

NCBI chr12:84,056,276...84,064,444
Ensembl chr12:84,056,264...84,065,145

G

acyl-Coenzyme A oxidase 1, palmitoyl

increases expression
multiple interactions

Triiodothyronine results in increased expression of ACOX1 mRNA
[BMS201038 co-treated with Triiodothyronine] results in increased expression of ACOX1 mRNA

NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871

G

acyl-CoA synthetase long-chain family member 1

increases expression

Triiodothyronine results in increased expression of ACSL1 mRNA

NCBI chr 8:46,924,214...46,989,088
Ensembl chr 8:46,924,074...46,989,088

G

acyl-CoA synthetase long-chain family member 5

increases expression

Triiodothyronine results in increased expression of ACSL5 mRNA

NCBI chr19:55,240,298...55,285,060
Ensembl chr19:55,240,370...55,286,152

G

activin A receptor, type II-like 1

increases expression

Triiodothyronine results in increased expression of ACVRL1 mRNA

NCBI chr15:101,026,403...101,043,217
Ensembl chr15:101,026,403...101,043,217

G

a disintegrin and metallopeptidase domain 11

increases expression

Triiodothyronine results in increased expression of ADAM11 mRNA

NCBI chr11:102,652,261...102,671,089
Ensembl chr11:102,652,265...102,671,088

G

ADAM metallopeptidase domain 12

increases expression

Triiodothyronine results in increased expression of ADAM12 mRNA

NCBI chr 7:133,484,928...133,826,859
Ensembl chr 7:133,484,928...133,833,875

G

ADAM metallopeptidase domain 15

decreases expression

Triiodothyronine results in decreased expression of ADAM15 mRNA

NCBI chr 3:89,246,947...89,257,589
Ensembl chr 3:89,245,849...89,257,303

G

ADAM metallopeptidase domain 19

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ADAM19 mRNA

NCBI chr11:45,945,329...46,038,174
Ensembl chr11:45,946,819...46,038,170

G

adducin 2

increases expression

Triiodothyronine results in increased expression of ADD2 mRNA

NCBI chr 6:86,005,663...86,101,391
Ensembl chr 6:86,005,663...86,101,391

G

adiponectin, C1Q and collagen domain containing

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]

NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778

G

adrenergic receptor, beta 1

increases expression

Triiodothyronine results in increased expression of ADRB1 mRNA; Triiodothyronine results in increased expression of ADRB1 protein

PMID:10217540 PMID:11090638

NCBI chr19:56,710,549...56,713,582
Ensembl chr19:56,710,631...56,721,545

G

adrenergic receptor, beta 2

multiple interactions
increases expression

bicalutamide inhibits the reaction [Triiodothyronine results in increased expression of ADRB2 protein]
Triiodothyronine results in increased expression of ADRB2 mRNA; Triiodothyronine results in increased expression of ADRB2 protein

NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030

G

adrenergic receptor, beta 3

multiple interactions
decreases expression
increases expression

Amiodarone inhibits the reaction [Triiodothyronine results in decreased expression of ADRB3 protein]
Triiodothyronine results in decreased expression of ADRB3 mRNA; Triiodothyronine results in decreased expression of ADRB3 protein
Triiodothyronine results in increased expression of ADRB3 protein

PMID:8836703 PMID:10217540

NCBI chr 8:27,715,804...27,720,833
Ensembl chr 8:27,715,804...27,740,644

G

aryl-hydrocarbon receptor

multiple interactions

Triiodothyronine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA]

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

A kinase anchor protein 12

increases expression

Triiodothyronine results in increased expression of AKAP12 mRNA

NCBI chr10:4,216,329...4,309,471
Ensembl chr10:4,216,380...4,309,470

G

akirin 2

increases expression

Triiodothyronine results in increased expression of AKIRIN2 mRNA

NCBI chr 4:34,550,615...34,566,930
Ensembl chr 4:34,550,937...34,566,908

G

aldo-keto reductase family 1, member C18

increases expression

Triiodothyronine results in increased expression of AKR1C3 mRNA

NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653

G

aldo-keto reductase family 1, member C21

increases expression

Triiodothyronine results in increased expression of AKR1C2 mRNA

NCBI chr13:4,624,074...4,636,542
Ensembl chr13:4,624,074...4,636,540

G

thymoma viral proto-oncogene 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine results in increased phosphorylation of AKT1 protein]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA]; Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased phosphorylation of AKT1 protein]

PMID:16021636 PMID:18096819 PMID:36868496

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

albumin

affects binding

Triiodothyronine binds to ALB protein

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

aldehyde dehydrogenase family 1, subfamily A3

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of ALDH1A3 mRNA

NCBI chr 7:66,040,640...66,077,225
Ensembl chr 7:66,040,638...66,077,265

G

aldehyde dehydrogenase family 3, subfamily A2

increases expression

Triiodothyronine results in increased expression of ALDH3A2 mRNA

NCBI chr11:61,114,240...61,158,267
Ensembl chr11:61,114,243...61,158,290

G

anti-Mullerian hormone

multiple interactions

Triiodothyronine affects the reaction [Propylthiouracil affects the expression of AMH mRNA]

NCBI chr10:80,641,074...80,643,513
Ensembl chr10:80,641,077...80,643,482

G

angiopoietin-like 8

multiple interactions

[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]

NCBI chr 9:21,746,806...21,748,643
Ensembl chr 9:21,746,806...21,748,643

G

apolipoprotein A-I

increases expression

Triiodothyronine results in increased expression of APOA1 protein

NCBI chr 9:46,139,928...46,141,767
Ensembl chr 9:46,139,878...46,141,764

G

apolipoprotein A-IV

multiple interactions

Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein]

NCBI chr 9:46,152,142...46,154,756
Ensembl chr 9:46,151,994...46,154,757

G

apolipoprotein E

multiple interactions

Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein]

NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113

G

amyloid beta precursor protein

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of APP mRNA; Triiodothyronine results in decreased expression of APP protein
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of APP protein modified form]
Tretinoin promotes the reaction [Triiodothyronine results in decreased secretion of APP protein]

PMID:17199430 PMID:36868496

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

aquaporin 1

increases expression

Triiodothyronine results in increased expression of AQP1 mRNA

NCBI chr 6:55,313,284...55,325,540
Ensembl chr 6:55,313,417...55,325,540

G

aquaporin 8

increases expression

Triiodothyronine results in increased expression of AQP8 mRNA

NCBI chr 7:123,061,517...123,067,226
Ensembl chr 7:123,061,514...123,067,227

G

androgen receptor

multiple interactions

Triiodothyronine inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

Rho guanine nucleotide exchange factor 25

decreases expression

Triiodothyronine results in decreased expression of ARHGEF25 mRNA

NCBI chr10:127,018,390...127,025,952
Ensembl chr10:127,018,394...127,025,952

G

ADP-ribosylation factor-like 4D

increases expression

Triiodothyronine results in increased expression of ARL4D mRNA

NCBI chr11:101,556,367...101,558,658
Ensembl chr11:101,556,367...101,558,658

G

arrestin domain containing 3

increases expression

Triiodothyronine results in increased expression of ARRDC3 mRNA

NCBI chr13:81,031,508...81,044,161
Ensembl chr13:81,031,503...81,044,161

G

asparaginase

increases expression

Triiodothyronine results in increased expression of ASPG mRNA

NCBI chr12:112,073,117...112,094,007
Ensembl chr12:112,073,113...112,093,993

G

abnormal spindle microtubule assembly

decreases expression

Triiodothyronine results in decreased expression of ASPM mRNA

NCBI chr 1:139,381,450...139,421,826
Ensembl chr 1:139,382,510...139,421,829

G

autophagy related 5

affects response to substance
increases expression

ATG5 protein affects the susceptibility to Triiodothyronine
Triiodothyronine results in increased expression of ATG5 mRNA; Triiodothyronine results in increased expression of ATG5 protein

NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287

G

autophagy related 7

increases expression

Triiodothyronine results in increased expression of ATG7 mRNA

NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575

G

ATPase, Na+/K+ transporting, beta 2 polypeptide

increases expression

Triiodothyronine results in increased expression of ATP1B2 mRNA

NCBI chr11:69,490,554...69,496,786
Ensembl chr11:69,490,562...69,496,768

G

ATPase, Ca++ transporting, cardiac muscle, slow twitch 2

multiple interactions
increases expression

THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of ATP2A2 mRNA]

NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288

G

arginine vasopressin

multiple interactions

[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]

NCBI chr 2:130,422,540...130,424,508
Ensembl chr 2:130,422,540...130,424,474

G

beta-site APP cleaving enzyme 1

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of BACE1 protein]

NCBI chr 9:45,749,878...45,775,694
Ensembl chr 9:45,749,878...45,775,697

G

BCL2-associated agonist of cell death

decreases expression

Triiodothyronine results in decreased expression of BAD protein

NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267

G

BCL2-associated X protein

decreases expression

Triiodothyronine results in decreased expression of BAX protein

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions
increases expression

Triiodothyronine promotes the reaction [tamibarotene results in decreased expression of BCL2 mRNA]
Triiodothyronine results in increased expression of BCL2 protein

PMID:11201846 PMID:16021636

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

B cell leukemia/lymphoma 2 related protein A1b

multiple interactions

Triiodothyronine promotes the reaction [tamibarotene results in increased expression of BCL2A1A mRNA]

NCBI chr 9:89,081,326...89,089,891
Ensembl chr 9:89,081,262...89,089,880

G

BCL2-like 1

increases expression

Triiodothyronine results in increased expression of BCL2L1 protein

NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648

G

B cell leukemia/lymphoma 3

increases expression

Triiodothyronine results in increased expression of BCL3 mRNA

NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695

G

bone morphogenetic protein 2

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of BMP2 mRNA

NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805

G

bone morphogenetic protein 6

multiple interactions
decreases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]

NCBI chr13:38,529,098...38,684,283
Ensembl chr13:38,529,083...38,684,278

G

bone morphogenetic protein 7

multiple interactions

[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA

NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114

G

bone morphogenetic protein 8b

multiple interactions

[mono-(2-ethylhexyl)phthalate co-treated with Triiodothyronine] results in increased expression of BMP8B mRNA

NCBI chr 4:122,998,101...123,019,887
Ensembl chr 4:122,998,958...123,025,892

G

calpain, small subunit 1

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CAPNS1 mRNA

NCBI chr 7:29,886,359...29,898,308
Ensembl chr 7:29,886,361...29,898,236

G

caspase 3

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of CASP3 protein
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]

PMID:16021636 PMID:32223187

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions
decreases activity

[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein; gadolinium chloride inhibits the reaction [[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [Triiodothyronine results in decreased activity of CAT protein]

PMID:12516873 PMID:23391542

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

coiled-coil domain containing 71

decreases expression

Triiodothyronine results in decreased expression of CCDC71 mRNA

NCBI chr 9:108,329,701...108,343,145
Ensembl chr 9:108,337,726...108,343,137

G

C-C motif chemokine ligand 5

multiple interactions
increases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]

NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344

G

cyclin A2

increases expression

Triiodothyronine results in increased expression of CCNA2 protein

NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299

G

cyclin D1

increases expression
multiple interactions

Triiodothyronine results in increased expression of CCND1 protein
Triiodothyronine results in increased expression of CCND1 mRNA; Triiodothyronine results in increased expression of CCND1 protein
THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of CCND1 mRNA]

PMID:16021636 PMID:20638743 PMID:28315333

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

cyclin E1

increases expression

Triiodothyronine results in increased expression of CCNE1 protein
Triiodothyronine results in increased expression of CCNE1 mRNA; Triiodothyronine results in increased expression of CCNE1 protein

NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959

G

cell division cycle 45

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CDC45 mRNA

NCBI chr16:18,599,202...18,632,371
Ensembl chr16:18,599,197...18,630,737

G

cyclin dependent kinase inhibitor 1A

multiple interactions
increases expression

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDKN1A mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CDKN1A mRNA]; Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein]

PMID:14761676 PMID:22383522

NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701

G

cyclin dependent kinase inhibitor 1B

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of CDKN1B mRNA; Triiodothyronine results in decreased expression of CDKN1B protein
THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein]

PMID:16021636 PMID:20638743

NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476

G

CCAAT/enhancer binding protein alpha

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]

NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353

G

centrosomal protein 15

increases expression

Triiodothyronine results in increased expression of CEP15 mRNA

NCBI chr14:10,147,278...10,185,610
Ensembl chr14:10,166,532...10,185,590
Ensembl chr14:10,166,532...10,185,590

G

carboxylesterase 2C

increases expression

Triiodothyronine results in increased expression of CES2C mRNA

NCBI chr 8:105,573,700...105,581,115
Ensembl chr 8:105,573,700...105,581,115

G

glycoprotein hormones, alpha subunit

multiple interactions
decreases expression

Phenelzine inhibits the reaction [Triiodothyronine results in decreased expression of CGA mRNA]; Triiodothyronine inhibits the reaction [Phenelzine results in increased expression of CGA mRNA]

NCBI chr 4:34,893,779...34,907,374
Ensembl chr 4:34,893,779...34,907,370

G

checkpoint kinase 1

increases phosphorylation

Triiodothyronine analog results in increased phosphorylation of CHEK1 protein

NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361

G

carbohydrate sulfotransferase 1

increases expression

Triiodothyronine results in increased expression of CHST1 mRNA

NCBI chr 2:92,429,978...92,445,597
Ensembl chr 2:92,430,052...92,445,595

G

clusterin

increases expression

Triiodothyronine results in increased expression of CLU mRNA

NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996

G

collagen, type X, alpha 1

multiple interactions
increases expression

ciglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA]; troglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA]

NCBI chr10:34,265,977...34,273,081
Ensembl chr10:34,265,977...34,273,081

G

collagen, type I, alpha 1

multiple interactions
increases expression

Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]
Triiodothyronine results in increased expression of COL1A1 mRNA

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type VI, alpha 3

increases expression

Triiodothyronine results in increased expression of COL6A3 mRNA

NCBI chr 1:90,694,582...90,771,710
Ensembl chr 1:90,693,645...90,771,693

G

coenzyme Q10B

increases expression

Triiodothyronine results in increased expression of COQ10B mRNA

NCBI chr 1:55,091,929...55,111,861
Ensembl chr 1:55,091,929...55,111,861

G

cytochrome c oxidase subunit 4I1

increases expression
multiple interactions

Triiodothyronine results in increased expression of COX4I1 protein
Chloroquine promotes the reaction [Triiodothyronine results in increased expression of COX4I1 protein]

NCBI chr 8:121,394,964...121,400,948
Ensembl chr 8:121,394,961...121,400,946

G

carnitine palmitoyltransferase 1a, liver

increases expression
multiple interactions

Triiodothyronine results in increased expression of CPT1A mRNA
Triiodothyronine results in increased expression of CPT1A mRNA; Triiodothyronine results in increased expression of CPT1A protein
resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]
[BMS201038 co-treated with Triiodothyronine] results in increased expression of CPT1A mRNA; Resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]

PMID:23209300 PMID:25048947 PMID:34902352

NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733

G

carnitine palmitoyltransferase 1b, muscle

increases expression

Triiodothyronine results in increased expression of CPT1B mRNA

NCBI chr15:89,300,608...89,310,065
Ensembl chr15:89,300,608...89,310,066

G

calcium release activated channel regulator 2B

decreases expression

Triiodothyronine results in decreased expression of CRACR2B mRNA

NCBI chr 7:141,041,007...141,046,526
Ensembl chr 7:141,041,007...141,046,526

G

carnitine acetyltransferase

increases expression

Triiodothyronine results in increased expression of CRAT mRNA

NCBI chr 2:30,290,483...30,305,602
Ensembl chr 2:30,290,483...30,305,825

G

citrate synthase

multiple interactions
decreases activity

[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA
Triiodothyronine results in decreased activity of CS protein

PMID:1153425 PMID:33091441

NCBI chr10:128,173,596...128,198,351
Ensembl chr10:128,173,603...128,198,348

G

cysteine sulfinic acid decarboxylase

increases expression

Triiodothyronine results in increased expression of CSAD mRNA

NCBI chr15:102,085,432...102,112,685
Ensembl chr15:102,085,434...102,113,159

G

c-src tyrosine kinase

multiple interactions

CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]]

NCBI chr 9:57,533,929...57,560,758
Ensembl chr 9:57,533,929...57,560,914

G

cathepsin E

increases expression

Triiodothyronine results in increased expression of CTSE mRNA

NCBI chr 1:131,566,052...131,603,245
Ensembl chr 1:131,566,044...131,603,243

G

C-X-C motif chemokine ligand 15

increases expression

Triiodothyronine results in increased expression of CXCL8 mRNA

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

cytochrome c, somatic

multiple interactions

THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]

NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]

NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]

NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions
increases expression

Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA]

NCBI chr 9:54,073,221...54,175,448
Ensembl chr 9:54,073,221...54,175,394

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
Triiodothyronine results in increased expression of CYP1A1 mRNA

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression
multiple interactions

Triiodothyronine results in increased expression of CYP1A2 mRNA
Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 protein]

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 24, subfamily a, polypeptide 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of CYP24A1 mRNA
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of CYP24A1 mRNA]

NCBI chr 2:170,324,877...170,339,065
Ensembl chr 2:170,324,628...170,339,065

G

cytochrome P450, family 2, subfamily c, polypeptide 65

multiple interactions

Triiodothyronine promotes the reaction [CYP2C9 protein results in increased metabolism of Coumarins]

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases activity
increases expression

Triiodothyronine results in increased activity of CYP2E1 protein
Triiodothyronine results in increased expression of CYP2E1 protein

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 8, subfamily b, polypeptide 1

decreases expression

Triiodothyronine results in decreased expression of CYP8B1 mRNA

PMID:10393316 PMID:29357290

NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371

G

D site albumin promoter binding protein

increases expression

Triiodothyronine results in increased expression of DBP mRNA

NCBI chr 7:45,354,658...45,359,579
Ensembl chr 7:45,354,512...45,359,627

G

2-4-dienoyl-Coenzyme A reductase 2, peroxisomal

increases expression

Triiodothyronine results in increased expression of DECR2 mRNA

NCBI chr17:26,300,182...26,309,096
Ensembl chr17:26,300,182...26,309,311

G

deiodinase, iodothyronine, type I

affects abundance
increases expression
multiple interactions
affects metabolic processing
increases chemical synthesis

DIO1 gene SNP affects the abundance of Triiodothyronine
Triiodothyronine results in increased expression of DIO1 mRNA
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA]
[DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine]
DIO1 protein affects the metabolism of Triiodothyronine
Arsenic affects the reaction [Triiodothyronine results in increased expression of DIO1 mRNA]; Pentachlorophenol inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA]
DIO1 protein results in increased chemical synthesis of Triiodothyronine

PMID:15254343 PMID:16131326 PMID:17105838 PMID:18288313 PMID:21565810 More...

NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366

G

deiodinase, iodothyronine, type II

multiple interactions
decreases expression
increases expression
increases chemical synthesis

2,2',4,4',5-brominated diphenyl ether inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4',5-brominated diphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine; kaempferol promotes the reaction [DIO2 protein results in increased activity of and results in increased abundance of Triiodothyronine]
Triiodothyronine results in decreased expression of DIO2 mRNA
[Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA
Triiodothyronine results in increased expression of DIO2 mRNA
DIO2 protein results in increased chemical synthesis of Triiodothyronine

PMID:17327447 PMID:17615150 PMID:23397585 PMID:25646720 PMID:26004626 More...

NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812

G

deiodinase, iodothyronine type III

increases expression
multiple interactions

Triiodothyronine results in increased expression of DIO3 mRNA
Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of DIO3 mRNA]
[Aurothioglucose results in decreased activity of DIO3 protein] which affects the metabolism of Triiodothyronine; [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [xanthohumol results in decreased activity of DIO3 protein] which affects the metabolism of Triiodothyronine

PMID:23397585 PMID:25962824 PMID:34571837

NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531

G

distal-less homeobox 2

multiple interactions

[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of DLX2 mRNA

NCBI chr 2:71,373,752...71,377,095
Ensembl chr 2:71,373,752...71,377,098

G

deleted in malignant brain tumors 1

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DMBT1 mRNA

NCBI chr 7:130,633,787...130,723,357
Ensembl chr 7:130,633,776...130,723,357

G

dystrophia myotonica-protein kinase

increases expression

Triiodothyronine results in increased expression of DMPK mRNA

NCBI chr 7:18,817,571...18,827,746
Ensembl chr 7:18,817,774...18,827,746

G

dematin actin binding protein

increases expression

Triiodothyronine results in increased expression of DMTN mRNA

NCBI chr14:70,839,624...70,873,488
Ensembl chr14:70,838,703...70,873,418

G

dual specificity phosphatase 2

multiple interactions
decreases expression

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DUSP2 mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of DUSP2 mRNA]

NCBI chr 2:127,178,079...127,180,297
Ensembl chr 2:127,178,079...127,180,296

G

dynein, cytoplasmic 1 light intermediate chain 2

increases expression

Triiodothyronine results in increased expression of DYNC1LI2 mRNA

NCBI chr 8:105,144,306...105,170,415
Ensembl chr 8:105,144,312...105,169,679

G

enoyl coenzyme A hydratase 1, peroxisomal

increases expression

Triiodothyronine results in increased expression of ECH1 mRNA

NCBI chr 7:28,524,763...28,531,664
Ensembl chr 7:28,524,642...28,531,672

G

EF-hand calcium binding domain 3

decreases expression

Triiodothyronine results in decreased expression of EFCAB3 mRNA

NCBI chr11:104,576,533...105,008,365
Ensembl chr11:104,576,533...105,008,363

G

epidermal growth factor

multiple interactions

Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]

PMID:11742803 PMID:16150908

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

G

eukaryotic translation initiation factor 4E binding protein 1

decreases phosphorylation

Triiodothyronine results in decreased phosphorylation of EIF4EBP1 protein

NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702

G

echinoderm microtubule associated protein like 2

increases expression

Triiodothyronine results in increased expression of EML2 mRNA

NCBI chr 7:18,910,322...18,940,407
Ensembl chr 7:18,910,346...18,940,407

G

enolase 1, alpha non-neuron

increases expression

Triiodothyronine results in increased expression of ENO1 mRNA

NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
Ensembl chr18:150,321,178...150,333,336

G

endothelial PAS domain protein 1

increases expression

Triiodothyronine results in increased expression of EPAS1 mRNA

NCBI chr17:87,061,292...87,140,838
Ensembl chr17:87,061,128...87,140,838

G

erythrocyte membrane protein band 4.1 like 3

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EPB41L3 mRNA

NCBI chr17:69,382,642...69,596,986
Ensembl chr17:69,382,678...69,596,984

G

epiregulin

increases expression

Triiodothyronine results in increased expression of EREG mRNA

NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505

G

estrogen receptor 1 (alpha)

multiple interactions
increases expression
decreases expression

Tamoxifen inhibits the reaction [Triiodothyronine results in decreased expression of ESR1 mRNA]; Triiodothyronine binds to and results in increased activity of ESR1 protein
Triiodothyronine results in increased expression of ESR1 mRNA
[Chlorpyrifos co-treated with Triiodothyronine] results in increased expression of ESR1 mRNA; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of ESR1 mRNA]

PMID:19942988 PMID:33049310 PMID:34571837

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

estrogen receptor 2 (beta)

multiple interactions

[Arsenic co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of ESR2 mRNA; [bisphenol A co-treated with Zearalenone co-treated with Arsenic co-treated with enzacamene co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in increased expression of ESR2 mRNA; [enzacamene co-treated with Estradiol co-treated with Triiodothyronine] affects the expression of ESR2 mRNA; [Estradiol co-treated with Triiodothyronine] inhibits the reaction [bisphenol A results in decreased expression of ESR2 mRNA]; [Estradiol co-treated with Triiodothyronine] promotes the reaction [Zearalenone results in decreased expression of ESR2 mRNA]; [Zearalenone co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [Zearalenone results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in decreased expression of ESR2 mRNA
Triiodothyronine binds to and results in increased activity of ESR2 protein

PMID:27338438 PMID:33049310

NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033

G

ethylmalonic encephalopathy 1

increases expression

Triiodothyronine results in increased expression of ETHE1 mRNA

NCBI chr 7:24,286,968...24,308,350
Ensembl chr 7:24,286,968...24,308,350

G

eva-1 homolog C

increases expression

Triiodothyronine results in increased expression of EVA1C mRNA

NCBI chr16:90,623,607...90,701,997
Ensembl chr16:90,623,607...90,701,997

G

fatty acid binding protein 4, adipocyte

increases expression
multiple interactions

Triiodothyronine results in increased expression of FABP4 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]

PMID:15953391 PMID:33476690

NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636

G

fatty acid binding protein 5, epidermal

increases expression

Triiodothyronine results in increased expression of FABP5 mRNA

NCBI chr 3:10,077,645...10,081,670
Ensembl chr 3:10,077,608...10,081,667

G

fatty acid desaturase 2

increases expression

Triiodothyronine results in increased expression of FADS2 mRNA

NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110

G

family with sequence similarity 171, member B

decreases expression

Triiodothyronine results in decreased expression of FAM171B mRNA

NCBI chr 2:83,642,889...83,713,878
Ensembl chr 2:83,642,980...83,713,830

G

family with sequence similarity 83, member H

increases expression

Triiodothyronine results in increased expression of FAM83H mRNA

NCBI chr15:75,872,941...75,886,185
Ensembl chr15:75,872,942...75,886,185

G

fatty acid synthase

increases expression
multiple interactions

Triiodothyronine results in increased expression of FASN mRNA
[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of FASN mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]

PMID:15953391 PMID:33476690 PMID:34289950

NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373

G

farnesyl diphosphate farnesyl transferase 1

increases expression

Triiodothyronine results in increased expression of FDFT1 mRNA

NCBI chr14:63,382,599...63,419,136
Ensembl chr14:63,382,599...63,417,027

G

farnesyl diphosphate synthetase

increases expression

Triiodothyronine results in increased expression of FDPS mRNA

NCBI chr 3:89,000,895...89,009,274
Ensembl chr 3:89,000,895...89,009,266

G

fibroblast growth factor 1

multiple interactions

[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]

NCBI chr18:38,971,725...39,062,532
Ensembl chr18:38,971,726...39,062,525

G

fibroblast growth factor 18

multiple interactions

Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein]

NCBI chr11:33,066,970...33,097,400
Ensembl chr11:33,067,430...33,097,400

G

fibroblast growth factor 2

multiple interactions

Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:11742803 PMID:12805413 PMID:16150908

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

fibroblast growth factor 7

decreases expression

Triiodothyronine results in decreased expression of FGF7 mRNA

NCBI chr 2:125,876,578...125,933,105
Ensembl chr 2:125,876,578...125,933,105

G

fibroblast growth factor 9

multiple interactions

Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein]

NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177

G

fibroblast growth factor receptor 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of FGFR1 mRNA
Triiodothyronine results in increased expression of FGFR1 mRNA; Triiodothyronine results in increased expression of FGFR1 protein
Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Dactinomycin inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]]

PMID:12805413 PMID:16150908

NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734

G

fibroblast growth factor receptor 2

increases expression

Triiodothyronine results in increased expression of FGFR2 mRNA

NCBI chr 7:129,764,181...129,868,538
Ensembl chr 7:129,764,181...132,725,079

G

fibroblast growth factor receptor 3

increases expression

Triiodothyronine results in increased expression of FGFR3 mRNA

NCBI chr 5:33,879,068...33,894,412
Ensembl chr 5:33,879,018...33,894,412

G

FK506 binding protein 10

decreases expression

Triiodothyronine results in decreased expression of FKBP10 mRNA

NCBI chr11:100,306,520...100,315,666
Ensembl chr11:100,306,523...100,315,650

G

fibronectin leucine rich transmembrane protein 1

increases expression

Triiodothyronine results in increased expression of FLRT1 mRNA

NCBI chr19:7,064,829...7,143,548
Ensembl chr19:7,069,366...7,083,094

G

forkhead box O6

increases expression

Triiodothyronine results in increased expression of FOXO6 mRNA

NCBI chr 4:120,124,275...120,144,458
Ensembl chr 4:120,124,276...120,144,546

G

folylpolyglutamyl synthetase

increases expression

Triiodothyronine results in increased expression of FPGS mRNA

NCBI chr 2:32,572,621...32,594,163
Ensembl chr 2:32,572,621...32,594,157

G

follicle stimulating hormone beta

multiple interactions

FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA]

NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001

G

FXYD domain-containing ion transport regulator 2

increases expression

Triiodothyronine results in increased expression of FXYD2 mRNA

NCBI chr 9:45,311,007...45,321,576
Ensembl chr 9:45,310,967...45,321,576

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions
increases expression

(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA]

NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729

G

growth associated protein 43

increases expression

Triiodothyronine results in increased expression of GAP43 mRNA; Triiodothyronine results in increased expression of GAP43 protein

NCBI chr16:42,068,915...42,161,014
Ensembl chr16:42,068,805...42,161,014

G

glucosylceramidase beta 1

increases activity

Triiodothyronine results in increased activity of GBA1 protein

NCBI chr 3:89,110,235...89,119,944
Ensembl chr 3:89,110,235...89,116,273

G

GTP cyclohydrolase 1

increases expression

Triiodothyronine results in increased expression of GCH1 mRNA

NCBI chr14:47,391,352...47,426,870
Ensembl chr14:47,391,352...47,426,870

G

growth hormone

multiple interactions
increases expression

Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Amiodarone inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; bisphenol A promotes the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Dexamethasone promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Edetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]; Triiodothyronine results in increased expression of and results in increased secretion of GH protein; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]
Triiodothyronine results in increased expression of GH mRNA; Triiodothyronine results in increased expression of GH1 mRNA; Triiodothyronine results in increased expression of GH1 protein

PMID:2211641 PMID:2910914 PMID:10720163 PMID:15240998 PMID:17090972 More...

NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691

G

growth hormone releasing hormone

multiple interactions

Triiodothyronine promotes the reaction [Dexamethasone results in increased expression of GHRH mRNA]

NCBI chr 2:157,171,416...157,190,645
Ensembl chr 2:157,171,417...157,189,426

G

gap junction protein, alpha 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of GJA1 protein
[Triiodothyronine co-treated with Chlorpyrifos] results in increased expression of GJA1 mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in increased expression of GJA1 mRNA
Triiodothyronine results in increased expression of GJA1 mRNA

PMID:15685554 PMID:34571837

NCBI chr10:56,253,297...56,266,519
Ensembl chr10:56,253,426...56,278,609

G

predicted gene, 29797

decreases expression

Triiodothyronine results in decreased expression of C20ORF204 mRNA

NCBI chr 2:181,297,555...181,301,407
Ensembl chr 2:181,298,827...181,301,260

G

glycerophosphocholine phosphodiesterase 1

increases expression

Triiodothyronine results in increased expression of GPCPD1 mRNA

NCBI chr 2:132,371,002...132,420,173
Ensembl chr 2:132,371,002...132,429,649

G

glycerol phosphate dehydrogenase 2, mitochondrial

increases expression

Triiodothyronine results in increased expression of GPD2 mRNA

NCBI chr 2:57,127,690...57,260,731
Ensembl chr 2:57,127,647...57,260,731

G

glutamic pyruvic transaminase, soluble

multiple interactions

Triiodothyronine inhibits the reaction [BMS201038 results in increased expression of GPT protein]

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 3

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of GPX3 protein]

NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203

G

glutamate receptor, ionotropic, kainate 4

increases expression

Triiodothyronine results in increased expression of GRIK4 mRNA

NCBI chr 9:42,431,708...42,856,296
Ensembl chr 9:42,429,431...42,855,789

G

glycogen synthase kinase 3 beta

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased phosphorylation of GSK3B protein]

NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446

G

glutathione S-transferase, alpha 2 (Yc2)

multiple interactions

Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTA2 protein]

NCBI chr 9:78,238,300...78,254,474
Ensembl chr 9:78,238,300...78,263,070

G

glutathione S-transferase, pi 1

multiple interactions

Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTP1 protein]

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

glutathione S-transferase pi 3

decreases expression

Triiodothyronine results in decreased expression of GSTP3 mRNA

NCBI chr19:4,107,470...4,109,587
Ensembl chr19:4,107,477...4,109,569

G

GULP, engulfment adaptor PTB domain containing 1

decreases expression

Triiodothyronine results in decreased expression of GULP1 mRNA

NCBI chr 1:44,590,540...44,835,998
Ensembl chr 1:44,590,671...44,835,998

G

H1.5 linker histone, cluster member

increases expression

Triiodothyronine results in increased expression of H1-5 mRNA

NCBI chr13:21,964,002...21,964,795
Ensembl chr13:21,964,053...21,964,795

G

H2A.X variant histone

increases phosphorylation
multiple interactions

Triiodothyronine analog results in increased phosphorylation of H2AX protein
Triiodothyronine analog promotes the reaction [Cisplatin results in increased expression of H2AX protein]

NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374

G

hemoglobin alpha, adult chain 1

increases expression

Triiodothyronine results in increased expression of HBA-A1 mRNA

NCBI chr11:32,233,672...32,234,486
Ensembl chr11:32,233,511...32,234,465

G

hemoglobin, beta adult major chain

increases expression

Triiodothyronine results in increased expression of HBB mRNA

G

hemoglobin Z, beta-like embryonic chain

increases expression

Triiodothyronine results in increased expression of HBG1 mRNA

NCBI chr 7:103,490,845...103,492,369
Ensembl chr 7:103,490,844...103,492,371

G

hyperpolarization-activated, cyclic nucleotide-gated K+ 2

increases expression

Triiodothyronine results in increased expression of HCN2 mRNA

NCBI chr10:79,552,468...79,571,942
Ensembl chr10:79,552,468...79,571,942

G

histidine decarboxylase

decreases expression

Triiodothyronine results in decreased expression of HDC mRNA

NCBI chr 2:126,435,579...126,465,942
Ensembl chr 2:126,435,587...126,461,219

G

heart development protein with EGF-like domains 1

increases expression

Triiodothyronine results in increased expression of HEG1 mRNA

NCBI chr16:33,504,754...33,591,946
Ensembl chr16:33,504,740...33,591,946

G

hepatocyte growth factor

multiple interactions

[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA

NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150

G

hypoxia inducible factor 1, alpha subunit

increases expression

Triiodothyronine results in increased expression of HIF1A mRNA

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

HIG1 domain family, member 1A

increases expression

Triiodothyronine results in increased expression of HIGD1A mRNA

NCBI chr 9:121,677,623...121,686,862
Ensembl chr 9:121,677,629...121,687,428

G

histone cell cycle regulator

increases expression

Triiodothyronine results in increased expression of HIRA mRNA

NCBI chr16:18,695,500...18,789,059
Ensembl chr16:18,695,787...18,789,059

G

3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1

increases expression

Triiodothyronine results in increased expression of HMGCS1 mRNA

NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796

G

3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2

increases expression

Triiodothyronine results in increased expression of HMGCS2 mRNA

NCBI chr 3:98,187,747...98,218,054
Ensembl chr 3:98,187,751...98,218,054

G

heme oxygenase 1

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of HMOX1 protein]

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

heterogeneous nuclear ribonucleoprotein H3

increases expression

Triiodothyronine results in increased expression of HNRNPH3 mRNA

NCBI chr10:62,850,443...62,859,764
Ensembl chr10:62,850,443...62,859,996

G

lysine demethylase and nuclear receptor corepressor

increases expression

Triiodothyronine results in increased expression of HR mRNA

PMID:25172293 PMID:26096596

NCBI chr14:70,789,644...70,810,988
Ensembl chr14:70,789,652...70,810,988

G

HscB iron-sulfur cluster co-chaperone

decreases expression

Triiodothyronine results in decreased expression of HSCB mRNA

NCBI chr 5:110,976,945...110,987,647
Ensembl chr 5:110,976,936...110,987,643

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]

NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110

G

hormonally upregulated Neu-associated kinase

increases expression

Triiodothyronine results in increased expression of HUNK mRNA

NCBI chr16:90,182,550...90,296,443
Ensembl chr16:90,182,901...90,296,441

G

isocitrate dehydrogenase 1 (NADP+), soluble

increases expression

Triiodothyronine results in increased expression of IDH1 mRNA

NCBI chr 1:65,197,775...65,225,638
Ensembl chr 1:65,197,775...65,225,659

G

insulin-like growth factor 1

multiple interactions
increases expression
increases secretion

Estradiol inhibits the reaction [Triiodothyronine results in increased expression of IGF1 mRNA]; Estradiol inhibits the reaction [Triiodothyronine results in increased secretion of IGF1 protein]

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

insulin-like growth factor binding protein 2

increases expression

Triiodothyronine results in increased expression of IGFBP2 mRNA

NCBI chr 1:72,863,650...72,891,633
Ensembl chr 1:72,863,662...72,891,633

G

IgLON family member 5

increases expression

Triiodothyronine results in increased expression of IGLON5 mRNA

NCBI chr 7:43,122,325...43,139,635
Ensembl chr 7:43,122,328...43,139,499

G

interleukin 10

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 17A

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]

NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720

G

interleukin 1 alpha

increases expression

Triiodothyronine results in increased expression of IL1A mRNA

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

multiple interactions
increases expression

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL1B protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of IL1B protein]
Triiodothyronine results in increased expression of IL1B mRNA

PMID:29796989 PMID:32223187 PMID:32816093 PMID:33476690 PMID:36868496

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 24

increases expression

Triiodothyronine results in increased expression of IL24 mRNA

NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191

G

interleukin 6

multiple interactions

THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL6 protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of IL6 mRNA]

PMID:29796989 PMID:32223187 PMID:36868496

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

inhibin alpha

multiple interactions

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of INHA mRNA

NCBI chr 1:75,483,872...75,487,010
Ensembl chr 1:75,483,721...75,487,010

G

inhibin beta-B

multiple interactions
increases expression

FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA]

NCBI chr 1:119,343,193...119,349,978
Ensembl chr 1:119,343,195...119,349,978

G

insulin I

multiple interactions

(+)-JQ1 compound inhibits the reaction [[Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA]; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA; [Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA

PMID:26972250 PMID:33091441

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

insulin II

multiple interactions

[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

PMID:27605626 PMID:33476690

NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118

G

insulin induced gene 1

increases expression

Triiodothyronine results in increased expression of INSIG1 mRNA

NCBI chr 5:28,276,410...28,283,660
Ensembl chr 5:28,276,361...28,283,660

G

interferon regulatory factor 1

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of IRF1 mRNA

NCBI chr11:53,660,841...53,669,200
Ensembl chr11:53,660,841...53,669,200

G

integrin alpha M

multiple interactions

Triiodothyronine promotes the reaction [tamibarotene results in increased expression of ITGAM protein]

NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663

G

integrin beta 3

multiple interactions

ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]

NCBI chr11:104,498,826...104,561,302
Ensembl chr11:104,498,826...104,561,302

G

integrin beta 5

increases expression
decreases expression

Triiodothyronine results in increased expression of ITGB5 mRNA
Triiodothyronine results in decreased expression of ITGB5 mRNA

NCBI chr16:33,650,021...33,769,708
Ensembl chr16:33,650,035...33,769,708

G

inositol 1,3,4-triphosphate 5/6 kinase

increases expression

Triiodothyronine results in increased expression of ITPK1 mRNA

NCBI chr12:102,534,842...102,671,128
Ensembl chr12:102,534,841...102,671,189

G

inositol 1,4,5-trisphosphate receptor 1

increases expression

Triiodothyronine results in increased expression of ITPR1 mRNA

NCBI chr 6:108,190,044...108,528,077
Ensembl chr 6:108,190,057...108,528,070

G

Kdm5c adjacent non-coding transcript

increases expression

Triiodothyronine results in increased expression of KANTR mRNA

NCBI chr X:151,077,820...151,110,489
Ensembl chr X:151,077,824...151,110,491

G

potassium voltage-gated channel, shaker-related subfamily, member 1

increases expression

Triiodothyronine results in increased expression of KCNA1 mRNA

NCBI chr 6:126,613,426...126,622,764
Ensembl chr 6:126,617,360...126,623,347

G

potassium voltage-gated channel, shaker-related subfamily, member 4

decreases expression

Triiodothyronine results in decreased expression of KCNA4 mRNA

NCBI chr 2:107,120,934...107,157,149
Ensembl chr 2:107,120,984...107,128,847

G

potassium large conductance calcium-activated channel, subfamily M, alpha member 1

multiple interactions

[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein

NCBI chr14:23,342,356...24,055,173
Ensembl chr14:23,339,499...24,064,559

G

potassium channel tetramerisation domain containing 12

decreases expression

Triiodothyronine results in decreased expression of KCTD12 mRNA

NCBI chr14:103,214,017...103,220,073
Ensembl chr14:103,214,017...103,220,073

G

kinesin family member 1B

increases expression

Triiodothyronine results in increased expression of KIF1B mRNA

NCBI chr 4:149,260,776...149,392,762
Ensembl chr 4:149,260,776...149,392,150

G

Kruppel-like transcription factor 9

decreases expression
increases expression

Triiodothyronine results in decreased expression of KLF9 mRNA
Triiodothyronine results in increased expression of KLF9 mRNA

PMID:15507505 PMID:23397585 PMID:26096596 PMID:35172007

NCBI chr19:23,118,590...23,145,493
Ensembl chr19:23,118,590...23,145,498

G

keratin 13

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of KRT13 mRNA

NCBI chr11:100,008,153...100,012,392
Ensembl chr11:100,008,153...100,012,392

G

kynurenine aminotransferase 1

decreases activity

Triiodothyronine results in decreased activity of KYAT1 protein

NCBI chr 2:30,075,136...30,096,307
Ensembl chr 2:30,075,136...30,095,859

G

low density lipoprotein receptor

multiple interactions
increases expression

Amiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA]; desethylamiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA]
Triiodothyronine inhibits the reaction [Amiodarone results in decreased expression of LDLR protein]

PMID:9071962 PMID:9712728

NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215

G

leucine-rich repeat LGI family, member 4

increases expression

Triiodothyronine results in increased expression of LGI4 mRNA

NCBI chr 7:30,758,360...30,770,347
Ensembl chr 7:30,758,767...30,770,360

G

LIM homeobox protein 3

decreases expression

Triiodothyronine results in decreased expression of LHX3 mRNA

NCBI chr 2:26,090,224...26,098,261
Ensembl chr 2:26,090,224...26,098,301

G

lipase, hormone sensitive

increases expression

Triiodothyronine results in increased expression of LIPE mRNA

NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135

G

LIM and cysteine-rich domains 1

decreases expression

Triiodothyronine results in decreased expression of LMCD1 mRNA

NCBI chr 6:112,250,747...112,307,384
Ensembl chr 6:112,250,719...112,307,386

G

lipin 3

increases expression

Triiodothyronine results in increased expression of LPIN3 mRNA

NCBI chr 2:160,722,590...160,747,920
Ensembl chr 2:160,722,590...160,747,922

G

lipoprotein lipase

increases expression

Triiodothyronine results in increased expression of LPL mRNA

NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100

G

low density lipoprotein receptor-related protein 1

multiple interactions

Triiodothyronine inhibits the reaction [[Iodine deficiency co-treated with Propylthiouracil] results in decreased expression of LRP1 protein]

NCBI chr10:127,374,026...127,457,158
Ensembl chr10:127,374,030...127,457,017

G

lanosterol synthase

increases expression

Triiodothyronine results in increased expression of LSS mRNA

NCBI chr10:76,367,303...76,392,973
Ensembl chr10:76,367,422...76,392,972

G

leukotriene B4 receptor 1

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of LTB4R mRNA

NCBI chr14:56,002,154...56,005,951
Ensembl chr14:56,003,419...56,005,951

G

LYR motif containing 9

decreases expression

Triiodothyronine results in decreased expression of LYRM9 mRNA

NCBI chr11:78,717,421...78,734,725
Ensembl chr11:78,717,410...78,737,696

G

microtubule-associated protein 1 light chain 3 beta

increases expression
multiple interactions
increases lipidation

Triiodothyronine results in increased expression of MAP1LC3B mRNA
bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein]

NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499

G

mitogen-activated protein kinase 1

multiple interactions
increases expression

Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK1 mRNA]
Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12805413 PMID:16150908 PMID:28315333

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions
increases expression

Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK3 mRNA]
Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12805413 PMID:16150908 PMID:28315333

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

microtubule-associated protein tau

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of and results in increased phosphorylation of MAPT protein]

NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916

G

myoglobin

affects expression

Triiodothyronine affects the expression of MB mRNA

NCBI chr15:76,899,687...76,934,868
Ensembl chr15:76,899,687...76,934,870

G

myelin basic protein

increases expression

Triiodothyronine results in increased expression of MBP protein alternative form

NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762

G

malic enzyme 1, NADP(+)-dependent, cytosolic

increases expression

Triiodothyronine results in increased expression of ME1 mRNA

PMID:15953391 PMID:29357290

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

meiosis specific with coiled-coil domain

decreases expression

Triiodothyronine results in decreased expression of MEIOC mRNA

NCBI chr11:102,556,177...102,573,066
Ensembl chr11:102,554,542...102,573,063

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

Triiodothyronine results in increased expression of MFSD2A mRNA

NCBI chr 4:122,840,643...122,855,844
Ensembl chr 4:122,840,643...122,854,981

G

MIER family member 3

decreases expression

Triiodothyronine results in decreased expression of MIER3 mRNA

NCBI chr13:111,822,607...111,855,130
Ensembl chr13:111,817,513...111,855,130

G

antigen identified by monoclonal antibody Ki 67

multiple interactions
increases expression

U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MKI67 mRNA]

NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090

G

monocyte to macrophage differentiation-associated 2

increases expression

Triiodothyronine results in increased expression of MMD2 mRNA

NCBI chr 5:142,549,229...142,594,886
Ensembl chr 5:142,548,113...142,594,555

G

matrix metallopeptidase 11

multiple interactions
increases expression

(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA]

NCBI chr10:75,759,056...75,768,336
Ensembl chr10:75,759,056...75,772,330

G

matrix metallopeptidase 2

multiple interactions

Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein]
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA

PMID:18031379 PMID:33091441

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

myeloperoxidase

multiple interactions

[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased activity of MPO protein

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

musashi RNA-binding protein 1

multiple interactions

[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of MSI1 mRNA

NCBI chr 5:115,567,734...115,593,757
Ensembl chr 5:115,567,658...115,593,757

G

mechanistic target of rapamycin kinase

decreases phosphorylation

Triiodothyronine results in decreased phosphorylation of MTOR protein

NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140

G

myosin, heavy polypeptide 6, cardiac muscle, alpha

multiple interactions
increases expression

S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of MYH6 mRNA]

PMID:11577024 PMID:15578571 PMID:15652358

NCBI chr14:55,179,378...55,205,553
Ensembl chr14:55,179,378...55,204,384

G

myosin, heavy polypeptide 7, cardiac muscle, beta

multiple interactions
decreases expression

Triiodothyronine inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA]
Triiodothyronine results in decreased expression of MYH7 mRNA

PMID:11577024 PMID:15578571

NCBI chr14:55,208,141...55,232,083
Ensembl chr14:55,208,141...55,232,083

G

non-SMC condensin II complex, subunit G2

decreases expression

Triiodothyronine results in decreased expression of NCAPG2 mRNA

NCBI chr12:116,368,969...116,427,152
Ensembl chr12:116,369,022...116,427,351

G

nuclear receptor coactivator 1

multiple interactions

[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein]

NCBI chr12:4,297,362...4,569,452
Ensembl chr12:4,297,362...4,527,182

G

nuclear receptor coactivator 2

multiple interactions

Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein]

PMID:29146198 PMID:31566444

NCBI chr 1:13,209,329...13,444,451
Ensembl chr 1:13,209,329...13,444,307

G

nuclear receptor co-repressor 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]

NCBI chr11:62,207,132...62,348,200
Ensembl chr11:62,207,252...62,349,367

G

nuclear receptor co-repressor 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]

NCBI chr 5:125,094,217...125,256,302
Ensembl chr 5:125,094,217...125,256,283

G

NADH:ubiquinone oxidoreductase subunit A5

increases expression

Triiodothyronine results in increased expression of NDUFA5 mRNA

NCBI chr 6:24,518,661...24,527,689
Ensembl chr 6:24,518,665...24,528,012

G

neurofilament, light polypeptide

decreases expression

Triiodothyronine results in decreased expression of NEFL mRNA

NCBI chr14:68,321,312...68,326,544
Ensembl chr14:68,321,312...68,326,544

G

neurofilament, medium polypeptide

decreases expression

Triiodothyronine results in decreased expression of NEFM mRNA

NCBI chr14:68,356,994...68,362,453
Ensembl chr14:68,320,039...68,362,295

G

nuclear factor, erythroid derived 2, like 2

multiple interactions

[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of NFE2L2 protein]

PMID:33476690 PMID:36868496

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

increases activity
multiple interactions

Triiodothyronine results in increased activity of NFKB1 protein
Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of NFKB1 protein]

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions

[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

neuronatin

decreases expression

Triiodothyronine results in decreased expression of NNAT mRNA

NCBI chr 2:157,401,936...157,404,445
Ensembl chr 2:157,401,998...157,404,442

G

nephronectin

increases expression

Triiodothyronine results in increased expression of NPNT mRNA

NCBI chr 3:132,587,506...132,656,052
Ensembl chr 3:132,587,506...132,656,052

G

nuclear receptor subfamily 0, group B, member 2

increases expression

Triiodothyronine results in increased expression of NR0B2 mRNA

NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

Triiodothyronine binds to and results in increased activity of NR1I2 protein

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]

NCBI chr15:101,151,783...101,172,676
Ensembl chr15:101,152,150...101,172,676

G

neurogranin

increases expression
multiple interactions

Triiodothyronine results in increased expression of NRGN mRNA; Triiodothyronine results in increased expression of NRGN protein
Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of and results in decreased phosphorylation of NRGN protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of NRGN mRNA]

PMID:15708448 PMID:29796989

NCBI chr 9:37,455,789...37,464,041
Ensembl chr 9:37,455,788...37,464,200

G

neuropilin 1

increases expression

Triiodothyronine results in increased expression of NRP1 mRNA

NCBI chr 8:129,085,553...129,231,957
Ensembl chr 8:129,085,085...129,229,844

G

NAD(P) dependent steroid dehydrogenase-like

increases expression

Triiodothyronine results in increased expression of NSDHL mRNA

NCBI chr X:71,962,127...72,002,134
Ensembl chr X:71,962,163...72,002,120

G

NMDA receptor synaptonuclear signaling and neuronal migration factor

increases expression

Triiodothyronine results in increased expression of NSMF mRNA

NCBI chr 2:24,944,370...24,952,893
Ensembl chr 2:24,944,367...24,952,893

G

5' nucleotidase, ecto

increases expression
increases activity

Triiodothyronine results in increased expression of NT5E mRNA
Triiodothyronine results in increased activity of NT5E protein

NCBI chr 9:88,209,662...88,254,142
Ensembl chr 9:88,209,250...88,254,145

G

nudix hydrolase 7

increases expression

Triiodothyronine results in increased expression of NUDT7 mRNA

NCBI chr 8:114,860,314...114,881,471
Ensembl chr 8:114,860,297...114,881,479

G

nucleoporin 214

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of NUP214 mRNA

NCBI chr 2:31,864,446...31,943,204
Ensembl chr 2:31,864,448...31,943,987

G

occludin

increases expression

Triiodothyronine results in increased expression of OCLN mRNA

NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226

G

oligodendrocyte transcription factor 2

decreases expression

Triiodothyronine results in decreased expression of OLIG2 protein

NCBI chr16:91,016,745...91,025,567
Ensembl chr16:91,022,345...91,025,565

G

olfactory receptor family 51 subfamily E member 2

increases expression

Triiodothyronine results in increased expression of OLR59 mRNA

NCBI chr 7:102,389,928...102,408,678
Ensembl chr 7:102,387,718...102,408,678

G

oxidative stress induced growth inhibitor 1

increases expression

Triiodothyronine results in increased expression of OSGIN1 mRNA

NCBI chr 8:120,160,874...120,172,996
Ensembl chr 8:120,160,863...120,172,995

G

prolyl 4-hydroxylase, beta polypeptide

multiple interactions
affects binding

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine binds to P4HB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to P4HB protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Polychlorinated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to P4HB protein]

PMID:17928132 PMID:18515855 PMID:19374345 PMID:22201216

NCBI chr11:120,451,124...120,464,079
Ensembl chr11:120,451,124...120,464,079

G

peptidyl arginine deiminase, type IV

increases expression

Triiodothyronine results in increased expression of PADI4 mRNA

NCBI chr 4:140,472,819...140,501,514
Ensembl chr 4:140,473,176...140,501,547

G

poly (ADP-ribose) polymerase family, member 4

decreases expression

Triiodothyronine results in decreased expression of PARP4 mRNA

NCBI chr14:56,812,982...56,897,256
Ensembl chr14:56,813,076...56,897,251

G

phosphoenolpyruvate carboxykinase 1, cytosolic

multiple interactions
increases expression

SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]

PMID:21815645 PMID:23209300 PMID:30209975

NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066

G

proliferating cell nuclear antigen

affects binding
increases expression
multiple interactions

Triiodothyronine analog binds to PCNA protein; Triiodothyronine binds to PCNA protein
Triiodothyronine results in increased expression of PCNA protein
THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein]
Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein]

PMID:20638743 PMID:22383522

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

proprotein convertase subtilisin/kexin type 1

decreases expression

Triiodothyronine results in decreased expression of PCSK1 mRNA

NCBI chr13:75,237,407...75,282,980
Ensembl chr13:75,237,945...75,282,980

G

proprotein convertase subtilisin/kexin type 2

decreases expression

Triiodothyronine results in decreased expression of PCSK2 mRNA

NCBI chr 2:143,388,053...143,658,204
Ensembl chr 2:143,388,076...143,658,205

G

platelet derived growth factor receptor, alpha polypeptide

decreases expression

Triiodothyronine results in decreased expression of PDGFRA protein

NCBI chr 5:75,311,988...75,358,867
Ensembl chr 5:75,312,953...75,358,876

G

pyruvate dehydrogenase kinase, isoenzyme 4

multiple interactions
increases expression

resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]
resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]

NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309

G

pyruvate dehydrogenase phosphatase catalytic subunit 2

increases expression

Triiodothyronine results in increased expression of PDP2 mRNA

NCBI chr 8:105,318,104...105,325,658
Ensembl chr 8:105,318,083...105,325,658

G

paternally expressed 10

increases expression

Triiodothyronine results in increased expression of PEG10 mRNA

NCBI chr 6:4,747,306...4,760,517
Ensembl chr 6:4,747,306...4,760,517

G

peroxisomal biogenesis factor 5

increases expression

Triiodothyronine results in increased expression of PEX5 mRNA

NCBI chr 6:124,373,774...124,392,878
Ensembl chr 6:124,373,775...124,392,026

G

phosphofructokinase, platelet

increases expression

Triiodothyronine results in increased expression of PFKP mRNA

NCBI chr13:6,629,910...6,699,096
Ensembl chr13:6,629,804...6,698,813

G

phosphatase, orphan 1

increases expression

Triiodothyronine results in increased expression of PHOSPHO1 mRNA

NCBI chr11:95,715,326...95,722,966
Ensembl chr11:95,715,325...95,722,966

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta

increases expression

Triiodothyronine results in increased expression of PIK3CD mRNA

NCBI chr 4:149,733,625...149,787,023
Ensembl chr 4:149,733,625...149,787,028

G

phospholipase A2, group VI

increases expression

Triiodothyronine results in increased expression of PLA2G6 mRNA

NCBI chr15:79,170,428...79,212,915
Ensembl chr15:79,170,428...79,212,590

G

phospholipase D family member 5

increases expression

Triiodothyronine results in increased expression of PLD5 mRNA

NCBI chr 1:175,789,867...176,109,078
Ensembl chr 1:175,789,872...176,102,878

G

perilipin 2

increases expression

Triiodothyronine results in increased expression of PLIN2 mRNA

NCBI chr 4:86,545,147...86,588,518
Ensembl chr 4:86,566,623...86,588,297

G

perilipin 3

multiple interactions

[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]

NCBI chr17:56,585,962...56,597,511
Ensembl chr17:56,584,476...56,599,873

G

plexin C1

increases expression

Triiodothyronine results in increased expression of PLXNC1 mRNA

NCBI chr10:94,626,728...94,780,875
Ensembl chr10:94,626,728...94,780,697

G

peripheral myelin protein 22

increases expression

Triiodothyronine results in increased expression of PMP22 mRNA

NCBI chr11:63,019,808...63,050,373
Ensembl chr11:63,019,808...63,050,373

G

patatin-like phospholipase domain containing 2

increases expression
decreases phosphorylation

Triiodothyronine results in increased expression of PNPLA2 mRNA
Triiodothyronine results in decreased phosphorylation of PNPLA2 protein

NCBI chr 7:141,035,101...141,040,656
Ensembl chr 7:141,035,111...141,040,656

G

podocalyxin-like

increases expression

Triiodothyronine results in increased expression of PODXL mRNA

NCBI chr 6:31,496,428...31,540,872
Ensembl chr 6:31,496,423...31,540,916

G

polymerase (DNA-directed), delta 3, accessory subunit

multiple interactions

Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein]

NCBI chr 7:99,731,317...99,770,709
Ensembl chr 7:99,731,318...99,770,772

G

polymerase (DNA directed), gamma

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of POLG mRNA

NCBI chr 7:79,095,979...79,117,659
Ensembl chr 7:79,095,979...79,116,110

G

protein-O-mannosyltransferase 1

increases expression

Triiodothyronine results in increased expression of POMT1 mRNA

NCBI chr 2:32,126,321...32,145,017
Ensembl chr 2:32,126,602...32,145,017

G

POU domain, class 5, transcription factor 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of POU5F1 mRNA
Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA]

NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669

G

peroxisome proliferator activated receptor alpha

multiple interactions

[GW 7647 results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [pirinixic acid results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [Triiodothyronine co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Triiodothyronine inhibits the reaction [Acetaminophen results in decreased expression of PPARA mRNA]

PMID:19631232 PMID:25048947 PMID:33476690 PMID:35662663

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

peroxisome proliferator activator receptor delta

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]

NCBI chr17:28,451,715...28,520,446
Ensembl chr17:28,451,674...28,520,448

G

peroxisome proliferator activated receptor gamma

multiple interactions

Triiodothyronine inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]
Triiodothyronine binds to and results in increased activity of PPARG protein
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Triiodothyronine binds to and results in increased activity of PPARG protein

PMID:25048947 PMID:33049310 PMID:33476690

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

peroxisome proliferative activated receptor, gamma, coactivator 1 alpha

increases expression
multiple interactions

Triiodothyronine results in increased expression of PPARGC1A mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein

PMID:23209300 PMID:30209975 PMID:33091441 PMID:33476690

NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068

G

PR domain containing 16

increases expression
multiple interactions

Triiodothyronine results in increased expression of PRDM16 mRNA
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA

PMID:30209975 PMID:33091441

NCBI chr 4:154,400,579...154,721,851
Ensembl chr 4:154,400,582...154,721,330

G

proline arginine-rich end leucine-rich repeat

decreases expression

Triiodothyronine results in decreased expression of PRELP mRNA

NCBI chr 1:133,838,042...133,857,820
Ensembl chr 1:133,838,042...133,849,152

G

prickle planar cell polarity protein 2

decreases expression

Triiodothyronine results in decreased expression of PRICKLE2 mRNA

NCBI chr 6:92,347,876...92,683,233
Ensembl chr 6:92,347,889...92,683,136

G

prolactin

decreases expression
increases secretion
multiple interactions

Triiodothyronine results in decreased expression of PRL mRNA; Triiodothyronine results in decreased expression of PRL protein
Triiodothyronine results in increased secretion of PRL protein
bisphenol A inhibits the reaction [Triiodothyronine results in increased secretion of PRL protein]; Chlorodiphenyl (54% Chlorine) promotes the reaction [Triiodothyronine results in increased secretion of PRL protein]

PMID:3734668 PMID:17615682

NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188

G

prokineticin receptor 1

increases expression

Triiodothyronine results in increased expression of PROKR1 mRNA

NCBI chr 6:87,555,568...87,567,741
Ensembl chr 6:87,555,573...87,567,725

G

prostate stem cell antigen

multiple interactions
increases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA protein]
Triiodothyronine results in increased expression of PSCA mRNA; Triiodothyronine results in increased expression of PSCA protein

NCBI chr15:74,586,688...74,588,914
Ensembl chr15:74,586,688...74,588,918

G

prostaglandin-endoperoxide synthase 2

increases expression

Triiodothyronine results in increased expression of PTGS2 mRNA

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

RAB23, member RAS oncogene family

decreases expression

Triiodothyronine results in decreased expression of RAB23 mRNA

NCBI chr 1:33,758,991...33,781,642
Ensembl chr 1:33,758,968...33,781,645

G

RAB3B, member RAS oncogene family

increases expression

Triiodothyronine results in increased expression of RAB3B mRNA

NCBI chr 4:108,736,267...108,800,521
Ensembl chr 4:108,736,260...108,800,521

G

RAS-related protein 1a

multiple interactions

RAP1A protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of Triiodothyronine]

NCBI chr 3:105,634,576...105,708,740
Ensembl chr 3:105,634,583...105,708,652

G

retinoic acid receptor, beta

increases expression

Triiodothyronine results in increased expression of RARB mRNA

NCBI chr14:5,387,365...6,038,924
Ensembl chr14:5,650,540...6,038,924

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions
increases activity

Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of RELA protein]

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

retinol saturase (all trans retinol 13,14 reductase)

increases expression

Triiodothyronine results in increased expression of RETSAT mRNA

NCBI chr 6:72,575,585...72,584,471
Ensembl chr 6:72,575,458...72,585,408

G

ras homolog family member V

increases expression

Triiodothyronine results in increased expression of RHOV mRNA

NCBI chr 2:119,099,682...119,108,489
Ensembl chr 2:119,099,682...119,101,753

G

replication protein A2

increases phosphorylation

Triiodothyronine analog results in increased phosphorylation of RPA2 protein

NCBI chr 4:132,495,671...132,506,057
Ensembl chr 4:132,495,643...132,506,063

G

ribosomal protein S6 kinase, polypeptide 1

multiple interactions
decreases phosphorylation

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Triiodothyronine results in decreased phosphorylation of RPS6KB1 protein]

NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631

G

retinoid X receptor beta

increases expression

Triiodothyronine results in increased expression of RXRB mRNA

NCBI chr17:34,250,786...34,257,377
Ensembl chr17:34,250,786...34,257,373

G

retinoid X receptor gamma

increases expression

Triiodothyronine results in increased expression of RXRG mRNA

NCBI chr 1:167,425,902...167,467,191
Ensembl chr 1:167,425,953...167,467,192

G

S100 calcium binding protein A6 (calcyclin)

multiple interactions

S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA]

NCBI chr 3:90,520,491...90,531,797
Ensembl chr 3:90,520,189...90,531,488

G

sterol-C5-desaturase

increases expression

Triiodothyronine results in increased expression of SC5D mRNA

NCBI chr 9:42,162,888...42,175,607
Ensembl chr 9:42,162,891...42,175,552

G

stearoyl-Coenzyme A desaturase 1

increases expression

Triiodothyronine results in increased expression of SCD1 mRNA

NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318

G

serine (or cysteine) peptidase inhibitor, clade A, member 6

increases expression

Triiodothyronine results in increased expression of SERPINA6 mRNA

NCBI chr12:103,612,889...103,623,477
Ensembl chr12:103,612,889...103,623,471

G

serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7

affects binding

Triiodothyronine binds to SERPINA7 protein

PMID:20804816 PMID:21517007

NCBI chr X:137,979,998...137,985,985
Ensembl chr X:137,980,006...137,985,985

G

sigma non-opioid intracellular receptor 1

increases expression

Triiodothyronine results in increased expression of SIGMAR1 mRNA

NCBI chr 4:41,738,493...41,741,359
Ensembl chr 4:41,738,493...41,756,157

G

sirtuin 1

multiple interactions
increases expression
affects response to substance

SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]
Triiodothyronine results in increased expression of SIRT1 mRNA
SIRT1 protein affects the susceptibility to Triiodothyronine

NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483

G

solute carrier family 10, member 2

increases expression

Triiodothyronine results in increased expression of SLC10A2 mRNA

NCBI chr 8:5,133,219...5,155,287
Ensembl chr 8:5,133,219...5,155,351

G

solute carrier family 15 (oligopeptide transporter), member 1

multiple interactions
decreases expression

resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 mRNA]; resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 protein]
Triiodothyronine results in decreased expression of SLC15A1 mRNA; Triiodothyronine results in decreased expression of SLC15A1 protein

NCBI chr14:121,697,033...121,742,666
Ensembl chr14:121,697,033...121,742,664

G

solute carrier family 16 (monocarboxylic acid transporters), member 2

multiple interactions
increases uptake

bisphenol A inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; bosutinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Dasatinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Desipramine inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Genistein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Imatinib Mesylate inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Indocyanine Green inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Meclofenamic Acid inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Phloretin inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Sulfobromophthalein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]

NCBI chr X:102,741,020...102,865,594
Ensembl chr X:102,741,020...102,865,589

G

solute carrier family 16 (monocarboxylic acid transporters), member 3

increases expression

Triiodothyronine results in increased expression of SLC16A3 mRNA

NCBI chr11:120,839,310...120,849,826
Ensembl chr11:120,839,306...120,851,694

G

solute carrier family 16 (monocarboxylic acid transporters), member 6

increases expression
multiple interactions

Triiodothyronine results in increased expression of SLC16A6 mRNA
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC16A6 mRNA]

NCBI chr11:109,341,681...109,366,428
Ensembl chr11:109,341,681...109,364,424

G

solute carrier family 1 (glial high affinity glutamate transporter), member 2

increases expression

Triiodothyronine results in increased expression of SLC1A2 mRNA

NCBI chr 2:102,488,584...102,621,129
Ensembl chr 2:102,489,004...102,621,129

G

solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 25

increases expression

Triiodothyronine results in increased expression of SLC25A25 mRNA

NCBI chr 2:32,304,499...32,341,482
Ensembl chr 2:32,304,499...32,341,457

G

solute carrier family 2 (facilitated glucose transporter), member 1

increases expression

Triiodothyronine results in increased expression of SLC2A1 mRNA

NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180

G

solute carrier family 2 (facilitated glucose transporter), member 4

multiple interactions

[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein

NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014

G

solute carrier family 2 (facilitated glucose transporter), member 5

multiple interactions

[Triiodothyronine co-treated with Fructose] results in increased expression of SLC2A5 mRNA

NCBI chr 4:150,203,801...150,228,625
Ensembl chr 4:150,203,740...150,228,626

G

solute carrier family 38, member 2

increases expression

Triiodothyronine results in increased expression of SLC38A2 mRNA

NCBI chr15:96,585,267...96,597,609
Ensembl chr15:96,585,273...96,597,611

G

solute carrier family 43, member 2

increases expression

Triiodothyronine results in increased expression of SLC43A2 mRNA

NCBI chr11:75,420,741...75,468,401
Ensembl chr11:75,422,520...75,468,401

G

solute carrier family 51, beta subunit

increases expression
multiple interactions

Triiodothyronine results in increased expression of SLC51B mRNA
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC51B mRNA]

NCBI chr 9:65,320,035...65,330,055
Ensembl chr 9:65,319,996...65,330,237

G

solute carrier family 5 (sodium iodide symporter), member 5

decreases expression

Triiodothyronine results in decreased expression of SLC5A5 protein

NCBI chr 8:71,335,529...71,345,429
Ensembl chr 8:71,335,533...71,345,401

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 11

increases expression

Triiodothyronine results in increased expression of SLC7A11 mRNA

NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063

G

secretory leukocyte peptidase inhibitor

increases expression

Triiodothyronine results in increased expression of SLPI mRNA

NCBI chr 2:164,195,990...164,231,086
Ensembl chr 2:164,195,990...164,231,015

G

sushi, nidogen and EGF-like domains 1

increases expression

Triiodothyronine results in increased expression of SNED1 mRNA

NCBI chr 1:93,163,563...93,228,787
Ensembl chr 1:93,163,563...93,228,787

G

small nucleolar RNA, H/ACA box 28

decreases expression

Triiodothyronine results in decreased expression of SNORA28 mRNA

NCBI chr12:111,507,380...111,507,501
Ensembl chr12:111,507,375...111,507,501

G

superoxide dismutase 1, soluble

multiple interactions
decreases expression

Triiodothyronine inhibits the reaction [Paraquat results in decreased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA]
Triiodothyronine results in decreased expression of SOD1 mRNA

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

SRY (sex determining region Y)-box 10

multiple interactions

[pyriproxyfen metabolite co-treated with Triiodothyronine] results in decreased expression of SOX10 mRNA

NCBI chr15:79,039,113...79,048,690
Ensembl chr15:79,039,108...79,049,440

G

SRY (sex determining region Y)-box 9

multiple interactions
decreases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of SOX9 mRNA
Triiodothyronine results in decreased expression of SOX9 mRNA

NCBI chr11:112,673,036...112,678,583
Ensembl chr11:112,673,050...112,678,586

G

spen family transcription repressor

increases expression

Triiodothyronine results in increased expression of SPEN mRNA

NCBI chr 4:141,195,199...141,265,955
Ensembl chr 4:141,195,201...141,265,908

G

serine palmitoyltransferase, long chain base subunit 2

increases expression

Triiodothyronine results in increased expression of SPTLC2 mRNA

NCBI chr12:87,351,832...87,435,129
Ensembl chr12:87,351,832...87,435,129

G

sequestosome 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of SQSTM1 mRNA
[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]

PMID:24262987 PMID:30209975

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

Rous sarcoma oncogene

multiple interactions

SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]

NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782

G

sterol regulatory element binding transcription factor 1

multiple interactions
decreases expression
decreases activity

SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]

PMID:23209300 PMID:33476690

NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407

G

serine and arginine-rich splicing factor 3

decreases expression

Triiodothyronine results in decreased expression of SFRS3 mRNA

NCBI chr17:29,251,634...29,262,346
Ensembl chr17:29,251,602...29,262,347

G

steroidogenic acute regulatory protein

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of STAR mRNA; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]

PMID:21726595 PMID:34571837

NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010

G

StAR related lipid transfer domain containing 8

increases expression

Triiodothyronine results in increased expression of STARD8 mRNA

NCBI chr X:98,046,539...98,118,334
Ensembl chr X:98,046,854...98,118,334

G

signal transducer and activator of transcription 1

multiple interactions

Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein]

NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024

G

signal transducer and activator of transcription 5A

increases expression

Triiodothyronine results in increased expression of STAT5A mRNA

NCBI chr11:100,750,177...100,775,995
Ensembl chr11:100,750,177...100,775,995

G

signal transducer and activator of transcription 5B

increases expression

Triiodothyronine results in increased expression of STAT5B mRNA

NCBI chr11:100,671,557...100,741,407
Ensembl chr11:100,671,557...100,741,550

G

serine/threonine kinase 19

increases expression

Triiodothyronine results in increased expression of STK19 mRNA

NCBI chr17:35,042,969...35,055,879
Ensembl chr17:35,042,969...35,055,921

G

stimulated by retinoic acid gene 8

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of STRA8 mRNA
[Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA

NCBI chr 6:34,897,098...34,916,279
Ensembl chr 6:34,897,098...34,916,279

G

sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1

increases expression

Triiodothyronine results in increased expression of SULT2A1 mRNA

NCBI chr 7:13,530,171...13,571,335
Ensembl chr 7:13,530,171...13,571,334

G

sulfotransferase family 4A, member 1

increases metabolic processing

SULT4A1 protein results in increased metabolism of Triiodothyronine

NCBI chr15:83,960,298...83,989,955
Ensembl chr15:83,960,298...83,989,955

G

synaptonemal complex protein 1

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of SYCP1 mRNA
[Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA

NCBI chr 3:102,725,815...102,843,416
Ensembl chr 3:102,725,815...102,843,416

G

TATA-box binding protein associated factor 5 like

increases expression

Triiodothyronine results in increased expression of TAF5L mRNA

NCBI chr 8:124,723,049...124,748,136
Ensembl chr 8:124,723,057...124,748,136

G

transcriptional and immune response regulator

multiple interactions
increases expression

SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of TCIM mRNA]

NCBI chr 8:24,927,188...24,928,962
Ensembl chr 8:24,927,196...24,929,000

G

testis expressed gene 264 ER-phagy receptor

increases expression

Triiodothyronine results in increased expression of TEX264 mRNA

NCBI chr 9:106,535,945...106,563,151
Ensembl chr 9:106,535,945...106,563,126

G

transcription factor EB

increases expression

Triiodothyronine results in increased expression of TFEB mRNA

NCBI chr17:48,047,962...48,103,341
Ensembl chr17:48,047,955...48,103,344

G

thyroglobulin

decreases expression

Triiodothyronine results in decreased expression of TG protein

NCBI chr15:66,542,606...66,722,570
Ensembl chr15:66,542,602...66,722,570

G

transforming growth factor, beta 1

multiple interactions

Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein]; Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA

PMID:18031379 PMID:33476690

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

trans-golgi network protein

increases expression
decreases expression

Triiodothyronine results in increased expression of TGOLN2 mRNA
Triiodothyronine results in decreased expression of TGOLN2 mRNA

NCBI chr 6:72,585,403...72,593,983
Ensembl chr 6:72,585,415...72,593,983

G

thyroid hormone receptor alpha

multiple interactions
affects binding
increases activity
increases expression
decreases expression

(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRA protein]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRA protein]; [THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; bisphenol S inhibits the reaction [Triiodothyronine binds to THRA protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRA protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine binds to and results in increased activity of THRA protein; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein]
Triiodothyronine results in increased expression of THRA mRNA; Triiodothyronine results in increased expression of THRA protein
Triiodothyronine results in decreased expression of THRA mRNA
[bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRA mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRA mRNA; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to THRA protein]; THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine binds to and results in increased activity of THRA protein; Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of THRA mRNA]
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; [Triiodothyronine co-treated with Chlorpyrifos] results in decreased expression of THRA mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of THRA mRNA; CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]

PMID:7684602 PMID:9664232 PMID:11806713 PMID:12109914 PMID:12414890 More...

NCBI chr11:98,631,539...98,659,832
Ensembl chr11:98,631,464...98,659,832

G

thyroid hormone receptor beta

multiple interactions
increases expression
decreases expression
affects binding
increases response to substance
increases activity

(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRB protein]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,3,4,7,8-pentachlorodibenzofuran inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,4,6-tribromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-trichlorophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-triiodophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRB protein]; 4-nonylphenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; 4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 6-OH-BDE-47 inhibits the reaction [Triiodothyronine binds to THRB protein]; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Amiodarone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol A analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol AF inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol S analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol S analog inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol S inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol S inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; cyhalothrin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; deoxynivalenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein alternative form]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRB protein]; methoxyacetic acid promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRB protein]; pentabromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; systhane inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; T-2 Toxin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrachlorodian analog inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [Triiodothyronine binds to THRB protein]; Tretinoin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRB protein]; Triclosan inhibits the reaction [Triiodothyronine binds to THRB protein]; Triiodothyronine binds to and results in increased activity of THRB protein; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein]; Zearalenone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]
Triiodothyronine results in decreased expression of THRB mRNA
THRB protein results in increased susceptibility to Triiodothyronine
Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein]
Triiodothyronine results in increased expression of THRB mRNA; Triiodothyronine results in increased expression of THRB protein
[bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRB mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRB mRNA; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB protein]

PMID:2211641 PMID:8137729 PMID:11577024 PMID:11806713 PMID:12109914 More...

NCBI chr14:4,429,599...4,810,538
Ensembl chr14:4,431,611...4,809,435

G

thyroid hormone responsive

multiple interactions
increases expression

Triiodothyronine inhibits the reaction [Amiodarone results in increased expression of THRSP mRNA]
[Chlorpyrifos co-treated with Triiodothyronine] results in increased expression of THRSP mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in increased expression of THRSP mRNA
Triiodothyronine results in increased expression of THRSP mRNA

PMID:2721112 PMID:10357836 PMID:15953391 PMID:28478156 PMID:34571837

NCBI chr 7:97,062,140...97,066,757
Ensembl chr 7:97,062,145...97,066,937

G

transmembrane protein 184b

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of TMEM184B mRNA

NCBI chr15:79,244,884...79,287,503
Ensembl chr15:79,244,884...79,287,769

G

transmembrane protein 44

increases expression

Triiodothyronine results in increased expression of TMEM44 mRNA

NCBI chr16:30,330,673...30,369,643
Ensembl chr16:30,330,673...30,369,660

G

tumor necrosis factor

multiple interactions

[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF mRNA; [Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF protein; Hexachlorocyclohexane inhibits the reaction [Triiodothyronine results in increased expression of TNF protein]; Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of TNF protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of TNF mRNA]
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]

PMID:15019085 PMID:29796989 PMID:32223187 PMID:36868496

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor receptor superfamily, member 9

multiple interactions
increases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 protein]
Triiodothyronine results in increased expression of TNFRSF9 mRNA; Triiodothyronine results in increased expression of TNFRSF9 protein

NCBI chr 4:151,004,612...151,030,561
Ensembl chr 4:150,999,019...151,030,559

G

translocase of outer mitochondrial membrane 20

multiple interactions
increases expression

Chloroquine promotes the reaction [Triiodothyronine results in increased expression of TOMM20 protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein]

NCBI chr 8:127,657,414...127,672,671
Ensembl chr 8:127,657,417...127,672,594

G

thyroid peroxidase

decreases expression

Triiodothyronine results in decreased expression of TPO protein

NCBI chr12:30,104,658...30,182,983
Ensembl chr12:30,104,658...30,182,623

G

TNF receptor-associated factor 1

multiple interactions
increases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 protein]
Triiodothyronine results in increased expression of TRAF1 mRNA; Triiodothyronine results in increased expression of TRAF1 protein

NCBI chr 2:34,831,762...34,851,784
Ensembl chr 2:34,831,762...34,851,784

G

transferrin

multiple interactions

[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

tripartite motif-containing 46

increases expression

Triiodothyronine results in increased expression of TRIM46 mRNA

NCBI chr 3:89,141,476...89,153,655
Ensembl chr 3:89,141,484...89,153,616

G

thyroid stimulating hormone, beta subunit

decreases expression
multiple interactions
increases secretion

Triiodothyronine results in decreased expression of TSHB mRNA
[Triiodothyronine co-treated with 2,2',4,4'-tetrabromodiphenyl ether] results in decreased expression of TSHB mRNA alternative form
TSHB protein results in increased secretion of Triiodothyronine

PMID:7827627 PMID:9092800 PMID:11288978 PMID:27420076 PMID:28167136

NCBI chr 3:102,684,621...102,718,175
Ensembl chr 3:102,682,781...102,690,034

G

thyroid stimulating hormone receptor

decreases expression

Triiodothyronine results in decreased expression of TSHR protein

NCBI chr12:91,367,767...91,507,283
Ensembl chr12:91,351,337...91,516,582

G

tau tubulin kinase 1

increases expression

Triiodothyronine results in increased expression of TTBK1 mRNA

NCBI chr17:46,751,577...46,798,596
Ensembl chr17:46,753,374...46,798,601

G

titin

multiple interactions
affects expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine affects the expression of TTN mRNA]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA]

NCBI chr 2:76,534,324...76,812,901
Ensembl chr 2:76,534,324...76,812,891

G

transthyretin

affects binding

Triiodothyronine binds to TTR protein

PMID:20804816 PMID:21517007

NCBI chr18:20,797,266...20,807,383
Ensembl chr18:20,798,337...20,807,378

G

uncoupling protein 1 (mitochondrial, proton carrier)

multiple interactions
increases expression

(+)-JQ1 compound inhibits the reaction [[Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA]; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]
Triiodothyronine results in increased expression of UCP1 mRNA; Triiodothyronine results in increased expression of UCP1 protein
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [Triiodothyronine co-treated with Norepinephrine] results in increased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]

PMID:11742803 PMID:26972250 PMID:30209975 PMID:33091441 PMID:33476690

NCBI chr 8:84,016,977...84,025,085
Ensembl chr 8:84,016,981...84,025,081

G

uncoupling protein 2 (mitochondrial, proton carrier)

multiple interactions

THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]; Triiodothyronine promotes the reaction [Bezafibrate results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [carboprostacyclin results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [darglitazone results in increased expression of UCP2 mRNA]

PMID:12588052 PMID:25048947

NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227

G

UDP-glucose ceramide glucosyltransferase

increases activity

Triiodothyronine results in increased activity of UGCG protein

NCBI chr 4:59,189,452...59,222,833
Ensembl chr 4:59,189,257...59,222,833

G

UDP glucuronosyltransferase 1 family, polypeptide A1

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of UGT1A1 mRNA
Vitamin A inhibits the reaction [Triiodothyronine results in decreased expression of UGT1A1 mRNA]

NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A6B

multiple interactions
increases expression

Vitamin A inhibits the reaction [Triiodothyronine results in increased expression of UGT1A6 mRNA]

NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725

G

UTP20 small subunit processome component

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of UTP20 mRNA

NCBI chr10:88,582,469...88,662,676
Ensembl chr10:88,582,469...88,662,666

G

voltage-dependent anion channel 1

multiple interactions
increases expression

Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein]
Triiodothyronine results in increased expression of VDAC1 protein

NCBI chr11:52,251,905...52,280,224
Ensembl chr11:52,251,687...52,280,224

G

vascular endothelial growth factor A

multiple interactions

[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

wntless WNT ligand secretion mediator

increases expression

Triiodothyronine results in increased expression of WLS mRNA

NCBI chr 3:159,545,287...159,644,302
Ensembl chr 3:159,545,309...159,644,300

G

wingless-type MMTV integration site family, member 4

multiple interactions

[Triiodothyronine co-treated with Chlorpyrifos] results in decreased expression of WNT4 mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of WNT4 mRNA

NCBI chr 4:137,004,946...137,026,812
Ensembl chr 4:137,004,800...137,027,037

G

zinc finger CCCH type containing 7B

decreases expression

Triiodothyronine results in decreased expression of ZC3H7B mRNA

NCBI chr15:81,629,299...81,680,470
Ensembl chr15:81,629,258...81,680,461

G

zinc finger protein 113

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ZNF3 mRNA

NCBI chr 5:138,137,964...138,154,043
Ensembl chr 5:138,137,964...138,154,006

G

zinc finger protein 664

increases expression

Triiodothyronine results in increased expression of ZNF664 mRNA

NCBI chr 5:124,939,758...124,965,694
Ensembl chr 5:124,939,755...124,979,757

G

zinc finger, MIZ-type containing 1

increases expression

Triiodothyronine results in increased expression of ZMIZ1 mRNA

NCBI chr14:25,458,299...25,667,167
Ensembl chr14:25,459,609...25,667,167

3,3'-diiodothyronine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

deiodinase, iodothyronine, type I

multiple interactions

[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine]

NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366

3-nitrotyrosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 1 beta

multiple interactions

[Asbestos, Crocidolite co-treated with IL1B protein] results in increased abundance of 3-nitrotyrosine; [Asbestos, Serpentine co-treated with IL1B protein] results in increased abundance of 3-nitrotyrosine

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

iodotyrosine deiodinase

multiple interactions

3-nitrotyrosine inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr10:3,490,274...3,504,880
Ensembl chr10:3,490,240...3,504,877

alpha-methyl-L-dopa

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catechol-O-methyltransferase

increases methylation
decreases activity

COMT protein results in increased methylation of Methyldopa
Methyldopa results in decreased activity of COMT protein

PMID:7053299 PMID:11160877

NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602

G

glutathione S-transferase, mu 1

decreases activity

Methyldopa analog results in decreased activity of GSTM1 protein

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

glutathione S-transferase, pi 1

decreases activity

Methyldopa analog results in decreased activity of GSTP1 protein

NCBI chr19:4,085,411...4,087,912
Ensembl chr19:4,085,407...4,087,985

G

prolactin

increases expression
increases secretion

Methyldopa results in increased expression of PRL protein
Methyldopa results in increased secretion of PRL protein

PMID:1867878 PMID:7265421

NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188

G

renin 1 structural

decreases activity

Methyldopa results in decreased activity of REN protein

NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063

Leu-enkephalin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

dipeptidylpeptidase 3

increases cleavage
multiple interactions

DPP3 protein results in increased cleavage of Enkephalin, Leucine
spinorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine]; tynorphin inhibits the reaction [DPP3 protein results in increased cleavage of Enkephalin, Leucine]

NCBI chr19:4,957,257...4,978,315
Ensembl chr19:4,957,257...4,978,315

G

opioid receptor, delta 1

increases activity

Enkephalin, Leucine results in increased activity of OPRD1 protein

NCBI chr 4:131,834,980...131,872,042
Ensembl chr 4:131,838,037...131,871,797

G

opioid receptor, mu 1

increases activity

Enkephalin, Leucine results in increased activity of OPRM1 protein

NCBI chr10:6,708,593...6,988,209
Ensembl chr10:6,708,506...6,988,198

maculosin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2-associated X protein

multiple interactions

maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of BAX protein]

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

B cell leukemia/lymphoma 2

multiple interactions

maculosin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 protein]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

caspase 3

multiple interactions

maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 mRNA]; maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 protein]

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

catalase

multiple interactions

maculosin inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

glutathione reductase

multiple interactions

maculosin inhibits the reaction [Diethylnitrosamine results in decreased activity of GSR protein]

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

maculosin inhibits the reaction [Diethylnitrosamine results in increased expression of PIK3R1 protein modified form]

NCBI chr13:101,817,269...101,904,725
Ensembl chr13:101,817,071...101,904,725

G

phosphatase and tensin homolog

multiple interactions

maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of PTEN protein]

NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560

G

transformation related protein 53

multiple interactions

maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of TRP53 mRNA]; maculosin inhibits the reaction [Diethylnitrosamine results in decreased expression of TRP53 protein]

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

melevodopa

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catechol-O-methyltransferase

increases methylation

COMT protein results in increased methylation of levodopa methyl ester

NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602

G

dopamine receptor D1

multiple interactions

[Oxidopamine co-treated with levodopa methyl ester] promotes the reaction [Benserazide results in increased expression of DRD1 protein]

NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724

G

dopamine receptor D2

multiple interactions

[Oxidopamine co-treated with levodopa methyl ester] inhibits the reaction [Benserazide results in increased expression of DRD2 protein]

NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477

monoiodotyrosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

iodotyrosine deiodinase

increases metabolic processing
multiple interactions

IYD protein results in increased metabolism of Monoiodotyrosine
1,2-dinitrobenzene inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 1-monomyristin inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,2'-dihydroxy-6,6'-dinaphthyldisulfide inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,2'-methylenebis(4-methyl-6-tert-butylphenol) inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,2'-methylenebis(ethyl-6-tert-butylphenol) inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,4,5-trichlorophenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,4-bis(alpha,alpha-dimethylbenzyl)phenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,4-di-tert-butylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,6-di-tert-butylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 3,3',4',5-tetrachlorosalicylanilide inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 3-nitrotyrosine inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 4-nonylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 4-octylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 4-tert-octylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 6-O-palmitoylascorbic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; acid red 337 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Allura Red AC Dye inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; bisphenol A diglycidyl ether inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Bithionol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; brilliant blue inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Bromphenol Blue inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; C.I. Acid Red 114 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Cetrimonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; cetyl sulfate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Chlordecone inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Chlorhexidine inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Clomiphene inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; DDT inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dexon (fungicide), sodium salt inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; di-2-(ethylhexyl)phosphoric acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Dibutyl Phthalate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dichlone inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Dichlorophen inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Dicofol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; didecyldimethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dinocap inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Dioctyl Sulfosuccinic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Direct Red 81 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dodecylbenzenesulfonic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dodecyltrimethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Eosine I Bluish inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Eosine Yellowish-(YS) inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Fast Green FCF inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; fluorophene inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; heptylparaben inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; isostearic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Kathon 930 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; lauryl gallate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Linoleic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Masoprocol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; methyl linoleate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; methylbenzethonium chloride inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Methylene Blue inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; monoolein inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; morin inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Myristic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; N-dodecylmorpholine inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Nitrofurazone inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; o-Phthalaldehyde inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; octyl gallate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Oleic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Palmitic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; perfluorodecanoic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; perfluorooctane sulfonic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; perfluoroundecanoic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Riboflavin inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Sodium Dodecyl Sulfate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; sodium laureth sulfate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Sodium Tetradecyl Sulfate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Tamoxifen inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; tetrabromobisphenol A inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; tetrachlorodian inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; tetradecyltrimethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; texapon TH inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Tinopal CBS-X inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; tribromsalan inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Triclosan inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; triflumizol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; trioctylmethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Troglitazone inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr10:3,490,274...3,504,880
Ensembl chr10:3,490,240...3,504,877

thyroxine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

multiple interactions
affects activity

Thyroxine inhibits the reaction [Propylthiouracil results in decreased activity of AADAT protein]
Thyroxine affects the activity of AADAT protein

NCBI chr 8:60,958,877...60,998,711
Ensembl chr 8:60,958,966...60,998,711

G

ATP-binding cassette, sub-family member 2

decreases abundance

ABCC2 results in decreased abundance of Thyroxine

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

aryl-hydrocarbon receptor

multiple interactions

AHR affects the reaction [2,4,6-triphenyl-1-hexene results in increased abundance of Thyroxine]

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

thymoma viral proto-oncogene 1

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of AKT1 mRNA]; Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of and results in increased phosphorylation of AKT1 protein]; Thyroxine inhibits the reaction [Propylthiouracil results in increased phosphorylation of AKT1 protein]

PMID:35101570 PMID:37295576

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

albumin

affects binding
multiple interactions

Thyroxine binds to ALB protein
2,2',4,5'-tetrabromodiphenyl ether metabolite inhibits the reaction [Thyroxine binds to ALB protein]; Flame Retardants analog inhibits the reaction [Thyroxine binds to ALB protein]

PMID:20039755 PMID:21517007 PMID:29283575

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

anti-Mullerian hormone

multiple interactions

Thyroxine affects the reaction [Propylthiouracil affects the expression of AMH mRNA]

NCBI chr10:80,641,074...80,643,513
Ensembl chr10:80,641,077...80,643,482

G

apolipoprotein D

increases expression

Thyroxine results in increased expression of APOD mRNA; Thyroxine results in increased expression of APOD protein

NCBI chr16:31,115,010...31,133,626
Ensembl chr16:31,115,010...31,133,626

G

amyloid beta precursor protein

decreases cleavage
decreases expression

Thyroxine results in decreased cleavage of APP protein
Thyroxine results in decreased expression of APP mRNA; Thyroxine results in decreased expression of APP protein

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

BCL2-associated agonist of cell death

multiple interactions
decreases expression

[nano-diamino-tetrac co-treated with Resveratrol] inhibits the reaction [Thyroxine results in decreased expression of BAD mRNA]; Resveratrol inhibits the reaction [Thyroxine results in decreased expression of BAD mRNA]; Thyroxine inhibits the reaction [Resveratrol results in increased expression of BAD mRNA]

PMID:31336132 PMID:31883986

NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267

G

B cell leukemia/lymphoma 2

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of BCL2 protein]

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

catalase

multiple interactions
decreases expression
decreases activity

[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of CAT mRNA]; [Vitamin E co-treated with Curcumin] inhibits the reaction [Thyroxine results in decreased activity of CAT protein]; arotinolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Atenolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of CAT mRNA]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of CAT protein]; Thyroxine inhibits the reaction [Propylthiouracil results in decreased activity of CAT protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased activity of CAT protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of CAT protein]
Thyroxine results in decreased expression of CAT mRNA; Thyroxine results in decreased expression of CAT protein

PMID:2575990 PMID:18723006 PMID:19914224 PMID:34047416

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

cyclin D1

increases expression
multiple interactions

Thyroxine results in increased expression of CCND1 mRNA
[Resveratrol co-treated with nano-diamino-tetrac] inhibits the reaction [Thyroxine results in increased expression of CCND1 mRNA]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of CCND1 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of CCND1 mRNA]

PMID:31336132 PMID:31883986

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

CD274 antigen

increases expression
multiple interactions

Thyroxine results in increased expression of CD274 mRNA; Thyroxine results in increased expression of CD274 protein; Thyroxine results in increased expression of PDL1 mRNA; Thyroxine results in increased expression of PDL1 protein
[Resveratrol co-treated with nano-diamino-tetrac] inhibits the reaction [Thyroxine results in increased expression of PDL1 mRNA]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of CD274 mRNA]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of CD274 protein]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of PDL1 mRNA]; NSC 74859 inhibits the reaction [Thyroxine results in increased expression of PDL1 protein]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of PDL1 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of PDL1 protein]

PMID:29960019 PMID:31336132 PMID:31883986

NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495

G

cell death-inducing DNA fragmentation factor, alpha subunit-like effector A

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA

NCBI chr18:67,476,634...67,500,864
Ensembl chr18:67,476,674...67,500,855

G

cell death-inducing DFFA-like effector c

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA

NCBI chr 6:113,401,595...113,412,721
Ensembl chr 6:113,401,595...113,412,721

G

cytochrome P450, family 2, subfamily c, polypeptide 29

decreases activity

Thyroxine results in decreased activity of CYP2C8 protein

NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157

G

cytochrome P450, family 8, subfamily b, polypeptide 1

decreases expression

Thyroxine results in decreased expression of CYP8B1 mRNA

NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371

G

decorin

decreases expression

Thyroxine results in decreased expression of DCN mRNA

NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005

G

deiodinase, iodothyronine, type I

affects abundance
multiple interactions
increases expression
affects metabolic processing
increases metabolic processing

DIO1 gene SNP affects the abundance of Thyroxine
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine results in increased expression of DIO1 mRNA]
DIO1 protein affects the metabolism of Thyroxine
[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine]

PMID:15254343 PMID:17105838 PMID:21565810 PMID:27420076

NCBI chr 4:107,148,662...107,164,365
Ensembl chr 4:107,148,662...107,164,366

G

deiodinase, iodothyronine, type II

multiple interactions
decreases expression
decreases activity
increases metabolic processing
affects metabolic processing

2,2',4,4',5-brominated diphenyl ether inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4',5-brominated diphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; [Aurothioglucose results in decreased activity of DIO2 protein] which affects the metabolism of Thyroxine; [DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine; [xanthohumol results in decreased activity of DIO2 protein] which affects the metabolism of Thyroxine; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Thyroxine results in decreased activity of DIO2 protein]; lactacystin inhibits the reaction [Thyroxine results in decreased activity of DIO2 protein]; Thyroxine results in decreased expression of and results in decreased activity of DIO2 protein
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine results in decreased expression of DIO2 mRNA]
DIO2 protein mutant form affects the metabolism of Thyroxine

PMID:11108274 PMID:11425850 PMID:16728495 PMID:17615150 PMID:25962824 More...

NCBI chr12:90,691,326...90,705,812
Ensembl chr12:90,691,326...90,705,812

G

deiodinase, iodothyronine type III

increases activity
multiple interactions

Thyroxine results in increased activity of DIO3 protein
Hydrogen Peroxide promotes the reaction [Thyroxine results in increased activity of DIO3 protein]

NCBI chr12:110,245,664...110,247,531
Ensembl chr12:110,245,502...110,247,531

G

dentin matrix protein 1

increases expression

Thyroxine results in increased expression of DMP1 mRNA

NCBI chr 5:104,345,441...104,361,968
Ensembl chr 5:104,350,479...104,361,968

G

dual oxidase 1

decreases expression

Thyroxine results in decreased expression of DUOX1 protein

NCBI chr 2:122,143,525...122,178,454
Ensembl chr 2:122,146,153...122,178,453

G

dual oxidase 2

decreases expression

Thyroxine results in decreased expression of DUOX2 protein

NCBI chr 2:122,109,727...122,129,221
Ensembl chr 2:122,109,728...122,128,930

G

fibroblast growth factor 1

increases expression

Thyroxine results in increased expression of FGF1 mRNA

NCBI chr18:38,971,725...39,062,532
Ensembl chr18:38,971,726...39,062,525

G

fibroblast growth factor 2

increases expression

Thyroxine results in increased expression of FGF2 mRNA

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

FMS-like tyrosine kinase 1

decreases expression

Thyroxine results in decreased expression of FLT1 mRNA

NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821

G

growth associated protein 43

increases expression
multiple interactions

Thyroxine results in increased expression of GAP43 mRNA
Thyroxine inhibits the reaction [Ethanol results in decreased expression of GAP43 mRNA]

NCBI chr16:42,068,915...42,161,014
Ensembl chr16:42,068,805...42,161,014

G

growth hormone

decreases abundance
multiple interactions

GH1 protein results in decreased abundance of Thyroxine
[2,2',4,4'-tetrabromodiphenyl ether co-treated with Thyroxine] results in increased expression of GH mRNA

PMID:17311540 PMID:17324600 PMID:27420076

NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691

G

glycerol phosphate dehydrogenase 2, mitochondrial

multiple interactions

Ipodate inhibits the reaction [Thyroxine results in increased activity of GPD2 protein]; Propylthiouracil inhibits the reaction [Thyroxine results in increased activity of GPD2 protein]

NCBI chr 2:57,127,690...57,260,731
Ensembl chr 2:57,127,647...57,260,731

G

glutamic pyruvic transaminase, soluble

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of GPT protein]

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutathione peroxidase 1

multiple interactions
increases activity
decreases activity
increases expression
decreases expression

[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in increased expression of GPX1 protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of GPX1 mRNA]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of GPX1 mRNA]
Thyroxine results in increased activity of GPX1 protein
Thyroxine results in decreased activity of GPX1 protein

NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542

G

glutathione reductase

multiple interactions
decreases activity
decreases expression

[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of GSR mRNA]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of GSR mRNA]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of GSR mRNA]
Thyroxine results in decreased activity of GSR protein
Thyroxine results in decreased expression of GSR mRNA; Thyroxine results in decreased expression of GSR protein

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

hes family bHLH transcription factor 1

multiple interactions

[Propylthiouracil results in increased abundance of Thyroxine] which results in increased expression of HES1 mRNA

NCBI chr16:29,883,259...29,886,614
Ensembl chr16:29,883,202...29,886,614

G

hes family bHLH transcription factor 5

multiple interactions

[Propylthiouracil results in increased abundance of Thyroxine] which results in increased expression of HES5 mRNA

NCBI chr 4:155,042,358...155,046,829
Ensembl chr 4:155,045,380...155,046,828

G

lysine demethylase and nuclear receptor corepressor

increases expression

Thyroxine results in increased expression of HR mRNA

NCBI chr14:70,789,644...70,810,988
Ensembl chr14:70,789,652...70,810,988

G

Harvey rat sarcoma virus oncogene

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of HRAS protein]

NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918

G

HtrA serine peptidase 1

increases expression

Thyroxine results in increased expression of HTRA1 mRNA

NCBI chr 7:130,537,933...130,587,388
Ensembl chr 7:130,537,841...130,587,390

G

interferon gamma

increases expression

Thyroxine results in increased expression of IFNG mRNA; Thyroxine results in increased expression of IFNG protein

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

insulin-like growth factor 1

increases expression

Thyroxine results in increased expression of IGF1 mRNA

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

insulin-like growth factor I receptor

increases expression
multiple interactions

Thyroxine results in increased expression of IGF1R protein
Vitamin E inhibits the reaction [Thyroxine results in increased expression of IGF1R protein]

NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416

G

interleukin 10

increases expression

Thyroxine results in increased expression of IL10 mRNA

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 1 beta

increases expression
multiple interactions

Thyroxine results in increased expression of IL1B mRNA
NSC 74859 inhibits the reaction [Thyroxine results in increased expression of IL1B mRNA]

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 6

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of IL6 protein]

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

insulin I

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA

NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914

G

integrin alpha V

multiple interactions

[Methamphetamine co-treated with Thyroxine] results in increased expression of ITGAV protein

NCBI chr 2:83,554,796...83,637,261
Ensembl chr 2:83,554,741...83,637,260

G

integrin beta 3

multiple interactions

ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]

NCBI chr11:104,498,826...104,561,302
Ensembl chr11:104,498,826...104,561,302

G

kinase insert domain protein receptor

decreases expression
increases expression

Thyroxine results in decreased expression of KDR mRNA
Thyroxine results in increased expression of KDR mRNA; Thyroxine results in increased expression of KDR protein

PMID:25298361 PMID:25499719

NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118

G

kynurenine aminotransferase 1

multiple interactions
affects activity

Thyroxine inhibits the reaction [Propylthiouracil results in decreased activity of KYAT1 protein]
Thyroxine affects the activity of KYAT1 protein

NCBI chr 2:30,075,136...30,096,307
Ensembl chr 2:30,075,136...30,095,859

G

mitogen-activated protein kinase 1

multiple interactions
increases phosphorylation
affects localization

NSC 74859 inhibits the reaction [Thyroxine results in increased phosphorylation of MAPK1 protein]
Thyroxine affects the localization of MAPK1 protein
tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK1 protein]

PMID:17984113 PMID:31336132

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 3

multiple interactions
increases phosphorylation
affects localization

NSC 74859 inhibits the reaction [Thyroxine results in increased phosphorylation of MAPK3 protein]
Thyroxine affects the localization of MAPK3 protein
tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK3 protein]

PMID:17984113 PMID:31336132

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

minichromosome maintenance complex component 7

increases expression

Thyroxine results in increased expression of MCM7 protein

NCBI chr 5:138,162,845...138,170,675
Ensembl chr 5:138,162,845...138,170,684

G

macrophage migration inhibitory factor (glycosylation-inhibiting factor)

increases expression
affects expression

Thyroxine results in increased expression of MIF protein
Thyroxine affects the expression of MIF mRNA

NCBI chr10:75,695,187...75,696,111
Ensembl chr10:75,695,187...75,696,074

G

matrix metallopeptidase 2

increases expression

Thyroxine results in increased expression of MMP2 mRNA

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 9

increases expression

Thyroxine results in increased expression of MMP9 mRNA

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

nuclear receptor coactivator 2

multiple interactions

Thyroxine promotes the reaction [THRA protein binds to NCOA2 protein]; Thyroxine promotes the reaction [THRB protein binds to NCOA2 protein]

NCBI chr 1:13,209,329...13,444,451
Ensembl chr 1:13,209,329...13,444,307

G

nuclear receptor co-repressor 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]

NCBI chr11:62,207,132...62,348,200
Ensembl chr11:62,207,252...62,349,367

G

nuclear receptor co-repressor 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]

NCBI chr 5:125,094,217...125,256,302
Ensembl chr 5:125,094,217...125,256,283

G

nitric oxide synthase 1, neuronal

increases expression

Thyroxine results in increased expression of NOS1 protein

NCBI chr 5:118,004,904...118,096,905
Ensembl chr 5:117,919,097...118,096,905

G

nitric oxide synthase 2, inducible

increases expression

Thyroxine results in increased expression of NOS2 protein

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nitric oxide synthase 3, endothelial cell

increases expression

Thyroxine results in increased expression of NOS3 mRNA; Thyroxine results in increased expression of NOS3 protein

NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

Thyroxine results in increased activity of NR1I2 protein
[Thyroxine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

G

nuclear receptor subfamily 1, group I, member 3

affects metabolic processing

NR1I3 protein affects the metabolism of Thyroxine

NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
increases expression

Thyroxine inhibits the reaction [Ethanol results in decreased expression of NR3C1 mRNA]
Thyroxine results in increased expression of NR3C1 mRNA

NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474

G

ornithine decarboxylase, structural 1

multiple interactions

Ipodate inhibits the reaction [Thyroxine results in increased activity of ODC1 protein]; Propylthiouracil inhibits the reaction [Thyroxine results in increased activity of ODC1 protein]

NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506

G

proprotein convertase subtilisin/kexin type 2

decreases expression

Thyroxine results in decreased expression of PCSK2 mRNA

NCBI chr 2:143,388,053...143,658,204
Ensembl chr 2:143,388,076...143,658,205

G

placental growth factor

increases expression

Thyroxine results in increased expression of PGF mRNA

NCBI chr12:85,213,413...85,224,087
Ensembl chr12:85,213,409...85,224,564

G

phosphate regulating endopeptidase homolog, X-linked

increases expression

Thyroxine results in increased expression of PHEX mRNA

NCBI chr X:155,945,071...156,198,282
Ensembl chr X:155,945,071...156,198,308

G

peripheral myelin protein 22

increases expression

Thyroxine results in increased expression of PMP22 mRNA

NCBI chr11:63,019,808...63,050,373
Ensembl chr11:63,019,808...63,050,373

G

cytochrome p450 oxidoreductase

increases expression

Thyroxine results in increased expression of POR mRNA

NCBI chr 5:135,698,894...135,764,180
Ensembl chr 5:135,698,887...135,764,180

G

peroxisome proliferator activated receptor gamma

multiple interactions

Thyroxine inhibits the reaction [Triclosan results in decreased expression of PPARG protein]

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
decreases expression

Thyroxine inhibits the reaction [resveratrol affects the localization of PTGS2 protein]
Thyroxine results in increased expression of PTGS2 protein
Thyroxine results in decreased expression of PTGS2 mRNA
[Resveratrol co-treated with nano-diamino-tetrac] promotes the reaction [Thyroxine results in decreased expression of PTGS2 mRNA]; nano-diamino-tetrac promotes the reaction [Thyroxine results in decreased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in decreased expression of PTGS2 mRNA]; Thyroxine inhibits the reaction [Resveratrol affects the localization of PTGS2 protein]; Thyroxine inhibits the reaction [Resveratrol results in increased expression of PTGS2 mRNA]

PMID:17984113 PMID:25298361 PMID:31336132 PMID:31883986

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

RAS-related protein 1a

multiple interactions

RAP1A protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of Thyroxine]

NCBI chr 3:105,634,576...105,708,740
Ensembl chr 3:105,634,583...105,708,652

G

retinoid X receptor alpha

affects binding

Thyroxine binds to RXRA protein

NCBI chr 2:27,566,457...27,653,331
Ensembl chr 2:27,566,452...27,652,969

G

succinate dehydrogenase complex, subunit A, flavoprotein (Fp)

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein

NCBI chr13:74,470,374...74,498,359
Ensembl chr13:74,470,373...74,498,399

G

sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin) 7A

increases expression

Thyroxine results in increased expression of SEMA7A mRNA

NCBI chr 9:57,846,879...57,870,148
Ensembl chr 9:57,847,395...57,870,148

G

serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7

multiple interactions
affects binding

3,5-dichlorobiphenyl metabolite inhibits the reaction [Thyroxine binds to SERPINA7 protein]; bisphenol A inhibits the reaction [Thyroxine binds to SERPINA7 protein]; tetrabromobisphenol A inhibits the reaction [Thyroxine binds to SERPINA7 protein]; tetrachlorodian inhibits the reaction [Thyroxine binds to SERPINA7 protein]

PMID:16478101 PMID:20804816 PMID:21517007 PMID:27528273

NCBI chr X:137,979,998...137,985,985
Ensembl chr X:137,980,006...137,985,985

G

sonic hedgehog

increases expression

Thyroxine results in increased expression of SHH mRNA

NCBI chr 5:28,661,838...28,672,099
Ensembl chr 5:28,661,813...28,672,254

G

sirtuin 1

increases expression

Thyroxine results in increased expression of SIRT1 protein

NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483

G

solute carrier family 2 (facilitated glucose transporter), member 4

multiple interactions

Thyroxine inhibits the reaction [Triclosan results in decreased expression of SLC2A4 protein]

NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014

G

solute carrier family 30, member 10

decreases chemical synthesis

SLC30A10 gene mutant form results in decreased chemical synthesis of Thyroxine

NCBI chr 1:185,187,045...185,200,959
Ensembl chr 1:185,187,045...185,200,959

G

solute carrier family 5 (sodium iodide symporter), member 5

decreases expression

Thyroxine results in decreased expression of SLC5A5 protein

NCBI chr 8:71,335,529...71,345,429
Ensembl chr 8:71,335,533...71,345,401

G

superoxide dismutase 1, soluble

multiple interactions
increases expression
increases activity
decreases activity
decreases expression

[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of SOD1 mRNA]; [Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in increased activity of SOD1 protein]; [Curcumin co-treated with Vitamin E] promotes the reaction [Thyroxine results in decreased activity of SOD1 protein]; Atenolol promotes the reaction [Thyroxine results in decreased expression of SOD1 protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of SOD1 mRNA]; Curcumin inhibits the reaction [Thyroxine results in increased activity of SOD1 protein]; Curcumin promotes the reaction [Thyroxine results in decreased activity of SOD1 protein]; Thyroxine inhibits the reaction [Zinc deficiency results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of SOD1 mRNA]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of SOD1 protein]; Vitamin E inhibits the reaction [Thyroxine results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Thyroxine results in increased expression of SOD1 protein]; Vitamin E promotes the reaction [Thyroxine results in decreased activity of SOD1 protein]
Thyroxine results in decreased expression of SOD1 mRNA; Thyroxine results in decreased expression of SOD1 protein

PMID:2575990 PMID:10381190 PMID:17447016 PMID:19914224

NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217

G

superoxide dismutase 2, mitochondrial

multiple interactions
decreases activity
decreases expression
increases expression

[Vitamin E co-treated with Curcumin] inhibits the reaction [Thyroxine results in decreased expression of SOD2 mRNA]; Atenolol inhibits the reaction [Thyroxine results in increased expression of SOD2 protein]; Curcumin inhibits the reaction [Thyroxine results in decreased activity of SOD2 protein]; Curcumin promotes the reaction [Thyroxine results in increased expression of SOD2 protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of SOD2 mRNA]; Vitamin E promotes the reaction [Thyroxine results in increased expression of SOD2 protein]

PMID:2575990 PMID:19914224

NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950

G

Rous sarcoma oncogene

multiple interactions

SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]

NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation

NSC 74859 inhibits the reaction [Thyroxine results in increased phosphorylation of STAT3 protein]

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

G

sulfotransferase family 4A, member 1

increases metabolic processing

SULT4A1 protein results in increased metabolism of Thyroxine

NCBI chr15:83,960,298...83,989,955
Ensembl chr15:83,960,298...83,989,955

G

synapsin I

multiple interactions

Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYN1 mRNA]

NCBI chr X:20,726,750...20,787,157
Ensembl chr X:20,726,750...20,787,243

G

synaptophysin

multiple interactions

Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYP mRNA]

NCBI chr X:7,504,819...7,519,495
Ensembl chr X:7,504,710...7,519,495

G

transforming growth factor, beta 1

increases expression
multiple interactions

Thyroxine results in increased expression of TGFB1 mRNA
NSC 74859 inhibits the reaction [Thyroxine results in increased expression of TGFB1 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of TGFB1 mRNA]

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

thyroid hormone receptor alpha

affects binding
multiple interactions
increases expression

Thyroxine binds to THRA protein
Thyroxine promotes the reaction [THRA protein binds to NCOA2 protein]
Thyroxine results in increased expression of THRA mRNA
[bisphenol A co-treated with Estradiol co-treated with Thyroxine] results in increased expression of THRA mRNA; [bisphenol A co-treated with Thyroxine] results in increased expression of THRA mRNA

PMID:23112079 PMID:23402801 PMID:27993100 PMID:31566444

NCBI chr11:98,631,539...98,659,832
Ensembl chr11:98,631,464...98,659,832

G

thyroid hormone receptor beta

multiple interactions
decreases expression
increases expression
increases activity
affects binding

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]; Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]; Thyroxine inhibits the reaction [Triiodothyronine binds to THRB protein]; Thyroxine promotes the reaction [THRB protein binds to NCOA2 protein]
Thyroxine results in decreased expression of THRB mRNA
Thyroxine results in increased expression of THRB mRNA
[bisphenol A co-treated with Estradiol co-treated with Thyroxine] results in increased expression of THRB mRNA; [bisphenol A co-treated with Thyroxine] results in increased expression of THRB mRNA
Thyroxine results in increased activity of THRB protein
Thyroxine binds to THRB protein

PMID:18584933 PMID:19457453 PMID:22227104 PMID:23112079 PMID:23402801 More...

NCBI chr14:4,429,599...4,810,538
Ensembl chr14:4,431,611...4,809,435

G

tumor necrosis factor

increases expression
decreases expression
multiple interactions

Thyroxine results in increased expression of TNF mRNA
Thyroxine results in decreased expression of TNF mRNA
Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of TNF protein]

PMID:23935926 PMID:24534949 PMID:34047416

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

thyroid peroxidase

multiple interactions

[Propylthiouracil results in decreased activity of TPO protein] which results in decreased chemical synthesis of and results in decreased abundance of Thyroxine

NCBI chr12:30,104,658...30,182,983
Ensembl chr12:30,104,658...30,182,623

G

transferrin

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

transformation related protein 53

affects localization
multiple interactions

Thyroxine affects the localization of TP53 protein modified form
tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of TP53 protein modified form]

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

transient receptor potential cation channel, subfamily M, member 7

decreases abundance

TRPM7 gene mutant form results in decreased abundance of Thyroxine

NCBI chr 2:126,633,478...126,718,181
Ensembl chr 2:126,633,485...126,718,150

G

thyroid stimulating hormone, beta subunit

multiple interactions
decreases expression

Clofibrate inhibits the reaction [Thyroxine results in decreased expression of TSHB protein]; Thyroxine inhibits the reaction [lead acetate results in decreased expression of TSHB protein]; Thyroxine inhibits the reaction [pexacerfont results in increased expression of TSHB protein]; Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of TSHB protein]
Thyroxine results in decreased expression of TSHB mRNA

PMID:18219302 PMID:21871911 PMID:27420076 PMID:33340518 PMID:34047416

NCBI chr 3:102,684,621...102,718,175
Ensembl chr 3:102,682,781...102,690,034

G

thyroid stimulating hormone receptor

decreases activity

Thyroxine results in decreased activity of TSHR protein

NCBI chr12:91,367,767...91,507,283
Ensembl chr12:91,351,337...91,516,582

G

transthyretin

multiple interactions
affects binding

2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',3,3',4,4',5-heptachlorobiphenyl inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,4'-tetrabromodiphenyl ether analog inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,5'-tetrabromodiphenyl ether metabolite inhibits the reaction [Thyroxine binds to TTR protein]; 2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Thyroxine binds to TTR protein]; 3,5-dichlorobiphenyl metabolite inhibits the reaction [Thyroxine binds to TTR protein]; 4-nonylphenol inhibits the reaction [Thyroxine binds to TTR protein]; bisphenol A inhibits the reaction [Thyroxine binds to TTR protein]; Diethylstilbestrol inhibits the reaction [Thyroxine binds to TTR protein]; Flame Retardants analog inhibits the reaction [Thyroxine binds to TTR protein]; Flame Retardants inhibits the reaction [Thyroxine binds to TTR protein]; Halogenated Diphenyl Ethers analog inhibits the reaction [Thyroxine binds to TTR protein]; PCB 180 inhibits the reaction [Thyroxine binds to TTR protein]; pentabromophenol inhibits the reaction [Thyroxine binds to TTR protein]; Pentachlorophenol inhibits the reaction [Thyroxine binds to TTR protein]; perfluoro-n-heptanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluoro-n-nonanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorobutanesulfonic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorobutyric acid affects the reaction [Thyroxine binds to TTR protein]; perfluorodecanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorododecanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorohexanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorooctane sulfonic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorooctane sulfonic acid inhibits the reaction [Thyroxine binds to TTR protein]; perfluorooctanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorooctanoic acid inhibits the reaction [Thyroxine binds to TTR protein]; perfluoroundecanoic acid affects the reaction [Thyroxine binds to TTR protein]; Polychlorinated Biphenyls analog inhibits the reaction [Thyroxine binds to TTR protein]; T-2 Toxin inhibits the reaction [Thyroxine binds to TTR protein]; tetrabromobisphenol A inhibits the reaction [Thyroxine binds to TTR protein]; tetrachlorodian inhibits the reaction [Thyroxine binds to TTR protein]; Thyroxine inhibits the reaction [1-anilino-8-naphthalenesulfonate binds to TTR protein]; Wastewater inhibits the reaction [Thyroxine binds to TTR protein]
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [Thyroxine binds to TTR protein]

PMID:10631123 PMID:10869457 PMID:16478101 PMID:16601080 PMID:18161906 More...

NCBI chr18:20,797,266...20,807,383
Ensembl chr18:20,798,337...20,807,378

G

uncoupling protein 2 (mitochondrial, proton carrier)

multiple interactions

Thyroxine promotes the reaction [darglitazone results in increased expression of UCP2 mRNA]

NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227

G

UDP glucuronosyltransferase 1 family, polypeptide A1

increases expression

Thyroxine results in increased expression of UGT1A1 mRNA

NCBI chr 1:88,139,681...88,147,724
Ensembl chr 1:88,139,681...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A9

multiple interactions

[Clofibrate co-treated with Thyroxine] results in increased activity of UGT1A9 protein

NCBI chr 1:87,998,501...88,147,724
Ensembl chr 1:87,998,522...88,146,719

G

vascular endothelial growth factor A

multiple interactions
increases expression
affects expression

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of VEGFA protein]
Thyroxine results in increased expression of VEGFA mRNA
Thyroxine affects the expression of VEGFA protein

PMID:25298361 PMID:25499719 PMID:35101570

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

tyrosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amyloid beta precursor protein

decreases abundance
multiple interactions

APP protein mutant form results in decreased abundance of Tyrosine
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Tyrosine]

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

citrate synthase

decreases activity

Tyrosine results in decreased activity of CS protein

NCBI chr10:128,173,596...128,198,351
Ensembl chr10:128,173,603...128,198,348

G

epidermal growth factor

multiple interactions

[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]

NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	22289
chemical entity	22288
group	22136
organic group	20326
organic univalent group	19775
organyl group	19775
proteinogenic amino-acid side-chain group	12623
4-hydroxybenzyl group	464
tyrosine +	464
Path 2
Term	Annotations
CHEBI ontology	22289
subatomic particle	22284
composite particle	22284
hadron	22284
baryon	22284
nucleon	22284
atomic nucleus	22284
atom	22284
group	22136
organic group	20326
organic univalent group	19775
organyl group	19775
proteinogenic amino-acid side-chain group	12623
4-hydroxybenzyl group	464
tyrosine +	464

paths to the root